Horizon Therapeutics Public (HZNP) 10-Q 9 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	HZNP
Entity Registrant Name	HORIZON PHARMA PLC
Entity Central Index Key	1,492,426
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		160,356,705

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 385,853	$ 859,616
Restricted cash	2,778	1,860
Accounts receivable, net	290,289	210,437
Inventories, net	180,202	18,376
Prepaid expenses and other current assets	17,482	15,858
Total current assets	876,604	1,106,147
Property and equipment, net	18,581	14,020
Intangible assets, net	1,983,760	1,616,110
In-process research and development	66,000	66,000
Other intangible assets, net	6,858	7,061
Goodwill	255,602	253,811
Deferred tax assets, net	4,347	2,278
Other assets	600	222
TOTAL ASSETS	3,205,494	3,058,588
CURRENT LIABILITIES:
Long-term debt—current portion	4,000	4,000
Accounts payable	69,671	16,590
Accrued expenses	89,140	100,046
Accrued trade discounts and rebates	224,370	183,769
Accrued royalties—current portion	54,588	51,700
Deferred revenues—current portion	1,155	1,447
Total current liabilities	442,924	357,552
LONG-TERM LIABILITIES:
Exchangeable notes, net	286,558	282,889
Long-term debt, net, net of current	849,622	849,867
Accrued royalties, net of current	172,445	123,519
Deferred revenues, net of current	8,579	8,785
Deferred tax liabilities, net	133,648	113,400
Other long-term liabilities	19,749	9,431
Total long-term liabilities	$ 1,470,601	$ 1,387,891
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares, $0.0001 nominal value; 300,000,000 shares authorized; 160,634,955 and 160,069,067 shares issued at March 31, 2016 and December 31, 2015, respectively, and 160,250,589 and 159,684,701 shares outstanding at March 31, 2016 and December 31, 2015, respectively	$ 16	$ 16
Treasury stock, 384,366 ordinary shares at March 31, 2016 and December 31, 2015	(4,585)	(4,585)
Additional paid-in capital	2,026,029	2,001,552
Accumulated other comprehensive loss	(2,898)	(2,651)
Accumulated deficit	(726,593)	(681,187)
Total shareholders’ equity	1,291,969	1,313,145
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	3,205,494	3,058,588
Developed Technology [Member]
CURRENT ASSETS:
Intangible assets, net	$ 1,976,902	$ 1,609,049

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Ordinary shares, nominal value	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	300,000,000	300,000,000
Ordinary shares, shares issued	160,634,955	160,069,067
Ordinary shares, shares outstanding	160,250,589	159,684,701
Treasury stock, ordinary shares	384,366	384,366

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net sales	$ 204,690	$ 113,141
Cost of goods sold	77,233	28,853
Gross profit	127,457	84,288
OPERATING EXPENSES:
Research and development	12,722	6,181
Sales and marketing	75,544	47,063
General and administrative	66,395	26,280
Total operating expenses	154,661	79,524
Operating (loss) income	(27,204)	4,764
OTHER EXPENSE, NET:
Interest expense, net	(19,458)	(10,032)
Foreign exchange loss	(173)	(837)
Loss on induced conversion of debt and debt extinguishment		(10,544)
Other expense, net	(14)	(991)
Total other expense, net	(19,645)	(22,404)
Loss before (benefit) expense for income taxes	(46,849)	(17,640)
(BENEFIT) EXPENSE FOR INCOME TAXES	(1,443)	1,913
NET LOSS	$ (45,406)	$ (19,553)
NET LOSS PER ORDINARY SHARE—Basic and diluted	$ (0.28)	$ (0.16)
WEIGHTED AVERAGE ORDINARY SHARES OUTSTANDING—Basic and diluted	159,904,416	125,650,593
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX
Foreign currency translation adjustments	$ (247)	$ 1,864
Other comprehensive (loss) income	(247)	1,864
COMPREHENSIVE LOSS	$ (45,653)	$ (17,689)

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (45,406)	$ (19,553)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization expense	50,642	18,335
Share-based compensation	27,745	6,674
Royalty accretion	9,359	3,044
Loss on induced conversions of debt and debt extinguishment		4,848
Amortization of debt discount and deferred financing costs	4,425	2,206
Foreign exchange loss	173	837
Other		102
Changes in operating assets and liabilities:
Accounts receivable	(69,838)	(53,443)
Inventories	7,317	3,088
Prepaid expenses and other current assets	(242)	(34,307)
Accounts payable	52,856	(18)
Accrued trade discounts and rebates	40,601	2,188
Accrued expenses and accrued royalties	(23,521)	(6,022)
Deferred revenues	(498)	(26)
Deferred income taxes	(2,657)	1,356
Other non-current assets and liabilities	3,225	(48)
Net cash provided by (used in) operating activities	54,181	(70,739)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for acquisitions, net of cash acquired	(514,814)
Purchases of property and equipment	(7,525)	(1,577)
Change in restricted cash	(918)	138
Net cash used in investing activities	(523,257)	(1,439)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of ordinary shares in connection with warrant exercises		9,924
Proceeds from the issuance of ordinary shares in connection with stock option exercises	919	1,789
Payment of employee withholding taxes relating to share-based awards	(4,185)	(1,215)
Net cash (used in) provided by financing activities	(4,266)	398,498
Effect of foreign exchange rate changes on cash	(421)	(916)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(473,763)	325,404
CASH AND CASH EQUIVALENTS, beginning of the period	859,616	218,807
CASH AND CASH EQUIVALENTS, end of the period	385,853	544,211
Supplemental cash flow information:
Cash paid for interest	9,534	7,311
Cash paid for income taxes	2,368	1,239
Cash paid for induced conversions and debt extinguishment		5,370
Supplemental non-cash flow information:
Purchases of property and equipment included in accounts payable and accrued expenses	2,851	1,033
Conversion of Convertible Senior Notes to ordinary shares		32,546
2015 Term Loan Facility [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of term loan facility	(1,000)
Exchangeable Senior Notes [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of Exchangeable Senior Notes	$ 387,200	$ 388,000

Basis of Presentation and Busin

Basis of Presentation and Business Overview	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and Business Overview	NOTE 1 – BASIS OF PRESENTATION AND BUSINESS OVERVIEW Basis of Presentation The unaudited condensed consolidated financial statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair statement of the financial statements have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The December 31, 2015 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. On September 19, 2014, the businesses of Horizon Pharma, Inc. (“HPI”) and Vidara Therapeutics International Public Limited Company (“Vidara”) were combined in a merger transaction (the “Vidara Merger”), accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with HPI treated as the acquiring company in the Vidara Merger for accounting purposes. As part of the Vidara Merger, a wholly-owned subsidiary of Vidara merged with and into HPI, with HPI surviving the Vidara Merger as a wholly-owned subsidiary of Vidara. Prior to the Vidara Merger, Vidara changed its name to Horizon Pharma plc (the “Company”). Upon the consummation of the Vidara Merger, the historical financial statements of HPI became the Company’s historical financial statements. On May 7, 2015, the Company completed its acquisition of Hyperion Therapeutics Inc. (“Hyperion”) in which the Company acquired all of the issued and outstanding shares of Hyperion’s common stock for $46.00 per share in cash or approximately $1.1 billion on a fully-diluted basis. Following the completion of the acquisition, Hyperion became a wholly-owned subsidiary of the Company and was renamed as Horizon Therapeutics, Inc. On January 13, 2016 completed its acquisition of The unaudited condensed consolidated financial statements presented herein include the results of operations of the acquired businesses from the date of acquisition. See Note 3 for further details of business acquisitions. Unless otherwise indicated or the context otherwise requires, references to the “Company”, “we”, “us” and “our” refer to Horizon Pharma plc and its consolidated subsidiaries, including its predecessor, HPI. All references to “Vidara” are references to Horizon Pharma plc (formerly known as Vidara Therapeutics International Public Limited Company) and its consolidated subsidiaries prior to the effective time of the Vidara Merger on September 19, 2014. The unaudited condensed consolidated financial statements presented herein include the accounts of the Company and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated. Business Overview The Company is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, primary care and rheumatology business units. The Company’s marketed medicines are ACTIMMUNE ® ® ® ® ® ® ® ® ® The Company developed DUEXIS and RAYOS, known as LODOTRA ® ® The Company’s medicines are distributed by retail and specialty pharmacies. Part of the Company’s commercial strategy for its primary care and rheumatology business units is to offer physicians the opportunity to have their patients fill prescriptions through pharmacies participating in the Company’s HorizonCares patient access program. This program does not involve the Company in the prescribing of medicines. The purpose of this program is solely to assist in ensuring that, when physicians determine that one of the Company’s medicines offers a potential clinical benefit to their patients and prescribe the medicine for an eligible patient, financial assistance may be available to reduce the commercial patient’s out-of-pocket costs. In the first three months of 2016, this resulted in approximately 96 percent of commercial patients having co-pay amounts of $10 or less when filling prescriptions for the Company’s medicines utilizing its patient access program. For commercial patients who are prescribed the Company’s primary care or rheumatology medicines, the HorizonCares program offers co-pay assistance when a third-party payor covers a prescription but requires an eligible patient to pay a co-pay or deductible, and offers full subsidization when a third-party payor rejects coverage for an eligible patient. For patients who are prescribed the Company’s orphan medicines, the Company’s patient access programs provide reimbursement support, a clinical nurse program, co-pay and other patient assistance. The aggregate commercial value of the Company’s patient access programs for the three months ended March 31, 2016 was $388.6 million. All pharmacies that fill prescriptions for the Company’s medicines are fully independent, including those that participate in HorizonCares. The Company does not own or possess any option to purchase an ownership stake in any pharmacy that distributes its medicines, and the Company’s relationship with each pharmacy is non-exclusive and arm’s length. All of the Company’s sales are processed through pharmacies independent of its business. The Company has a compliance program in place to address adherence with various laws and regulations relating to its sales, marketing and manufacturing of its medicines, as well as certain third-party relationships, including pharmacies. Specifically with respect to pharmacies, the compliance program utilizes a variety of methods and tools to monitor and audit pharmacies, including those that participate in the HorizonCares program, to confirm their activities, adjudication and practices are consistent with the Company’s compliance policies and guidance. The Company is a public limited company formed under the laws of Ireland. The Company operates through a number of international and U.S. subsidiaries with principal business purposes to either hold intellectual property assets, perform research and development or manufacturing operations, serve as distributors of the Company’s medicines or provide services and financial support to the Company. Revision of Prior Period Financial Statements In the course of preparing the Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2016, the Company determined that there had been an error in the presentation of the line titled “Foreign currency translation adjustments” for the previously reported three months ended March 31, 2015 (the “Affected Financial Statement”). The Affected Financial Statement presented foreign currency translation adjustment of $1,864,000 as a loss rather than income. Accounting Changes and Error Corrections, Assessing Materiality Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements For the Three Months Ended March 31, 2015 As reported As adjusted Net loss $ (19,553 ) $ (19,553 ) Foreign currency translation adjustments (1,864 ) $ 1,864 Other comprehensive (loss) income (1,864 ) 1,864 Comprehensive loss $ (21,417 ) $ (17,689 ) Recent Accounting Pronouncements From time to time, the Company adopts, as of the specified effective date, new accounting pronouncements issued by the FASB or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. As of December 31, 2015 As filed Reclassification As adjusted Other non-current assets $ 8,581 $ (8,359 ) $ 222 Exchangeable notes, net (283,675 ) 786 (282,889 ) Long-term debt, net, net of current (857,440 ) 7,573 (849,867 ) In April 2015, the FASB issued ASU No. 2015-05: Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB Issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	NOTE 2 – NET LOSS PER SHARE The following table presents basic and diluted net loss per share for the three months ended March 31, 2016 and 2015 (in thousands, except share and per share data): For the Three Months Ended March 31, 2016 2015 Basic and diluted loss per share calculation: Net loss $ (45,406 ) $ (19,553 ) Weighted average ordinary shares outstanding 159,904,416 125,650,593 Basic and diluted net loss per share $ (0.28 ) $ (0.16 ) Basic net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. Diluted earnings per share (“EPS”) reflects the potential dilution beyond shares for basic EPS that could occur if securities or other contracts to issue ordinary shares were exercised, converted into ordinary shares, or resulted in the issuance of ordinary shares that would have shared in the Company’s earnings. The potentially dilutive impact of the Horizon Pharma Investment Limited (“Horizon Investment”), a wholly-owned subsidiary of the Company, March 2015 private placement of $400.0 million aggregate principal amount of 2.50% Exchangeable Senior Notes due 2022 (the “Exchangeable Senior Notes”) is determined using a method similar to

Business Acquisitions

Business Acquisitions	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Business Acquisitions	NOTE 3 – BUSINESS ACQUISITIONS Crealta Acquisition On January 13, 2016, the Company completed its acquisition of all the membership interests of Crealta. The acquisition added two medicines, KRYSTEXXA and MIGERGOT, to the Company’s medicine portfolio. The Crealta acquisition further diversified the Company’s portfolio of medicines and aligned with its focus of acquiring value-enhancing, clinically differentiated, long-life medicines that treat orphan diseases. The total consideration for the acquisition was approximately $539.7 million, including cash acquired of $24.9 million, and was composed of the following (in thousands): Cash $ 536,181 Net settlements on the exercise of stock options and unrestricted units 3,526 Total consideration $ 539,707 During the three months ended March 31, 2016, the Company incurred $10.1 million in Crealta acquisition-related costs including advisory, legal, accounting, valuation, severance, retention bonuses and other professional and consulting fees and $10.0 million and $0.1 million were accounted for as “general and administrative” and “costs of goods sold”, respectively, in the condensed consolidated statement of comprehensive loss. Pursuant to ASC 805, the Company accounted for the Crealta acquisition as a business combination using the acquisition method of accounting. Identifiable assets and liabilities of Crealta, including identifiable intangible assets, were recorded based on their estimated fair values as of the date of the closing of the acquisition. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. Significant judgment was required in determining the estimated fair values of developed technology intangible assets, inventories and certain other assets and liabilities. Such preliminary valuation required estimates and assumptions including, but not limited to, estimating future cash flows and direct costs in addition to developing the appropriate discount rates and current market profit margins. The Company’s management believes the fair values recognized for the assets acquired and the liabilities assumed are based on reasonable estimates and assumptions. Accordingly, the unaudited purchase price adjustments are preliminary and are subject to further adjustments as additional information becomes available and as additional analyses are performed, and such further adjustments may be material. The following table summarizes the preliminary fair values assigned to the assets acquired and the liabilities assumed by the Company (in thousands): (Liabilities assumed) and assets acquired: Allocation Accounts payable and accrued expenses $ (4,543 ) Accrued trade discounts and rebates (1,424 ) Deferred tax liability (20,835 ) Other non-current liability (6,900 ) Contingent royalty liabilities (51,300 ) Cash and cash equivalents 24,893 Accounts receivable 10,014 Inventories 169,054 Prepaid expenses and other current assets 1,382 Developed technology 417,300 Other non-current assets 275 Goodwill 1,791 Fair value of consideration paid $ 539,707 Inventories acquired included raw materials, work in process and finished goods. Inventories were recorded at their preliminary estimated fair values. The fair value of finished goods has been determined based on the estimated selling price, net of selling costs and a margin on the selling costs. The fair value of work in process has been determined based on estimated selling price, net of selling costs and costs to complete the manufacturing, and a margin on the selling and manufacturing costs. The fair value of raw materials was estimated to equal the replacement cost. A step up in the value of inventory of $163.6 million was recorded in connection with the acquisition. During the three months ended March 31, 2016, the Company amortized $7.4 million of KRYSTEXXA and MIGERGOT inventory step-up. Other tangible assets and liabilities were valued at their respective carrying amounts as management believes that these amounts approximated their acquisition date fair values. Other non-current liability represents an assumed $6.9 million probable contingent liability. See Note 12 for further details. Identifiable intangible assets and liabilities acquired include developed technology and contingent royalties. The preliminary estimated fair values of the developed technology and contingent royalties represent preliminary valuations performed with the assistance of an independent appraisal firm based on management’s estimates, forecasted financial information and reasonable and supportable assumptions. Developed technology intangible assets reflect the estimated fair value of Crealta’s rights to its currently marketed medicines, KRYSTEXXA and MIGERGOT. The preliminary fair value of developed technology was determined using an income approach. The income approach explicitly recognizes that the fair value of an asset is premised upon the expected receipt of future economic benefits such as earnings and cash inflows based on current sales projections and estimated direct costs for Crealta’s medicines. Indications of value were developed by discounting these benefits to their acquisition-date worth at a discount rate of 27% for KRYSTEXXA and 23% for MIGERGOT. The fair value of the KRYSTEXXA and MIGERGOT developed technologies were capitalized as of the Crealta acquisition date and are subsequently being amortized over approximately 12 and 10 years, respectively, which are the periods in which over 90% of the estimated cash flows are expected to be realized. The Company has assigned a preliminary fair value to a contingent liability for royalties potentially payable under previously existing agreements related to KRYSTEXXA and MIGERGOT. The royalties for KRYSTEXXA are payable under the terms of a license agreement with Duke University (“Duke”) and Mountain View Pharmaceuticals (“MVP”). See Note 12 for details of the percentages of royalties payable under such agreements. The initial fair value of this liability was $51.3 million and was determined using a discounted cash flow analysis incorporating the estimated future cash flows of royalty payments resulting from future sales. The discount rate used was the same as for the fair value of the developed technology. The preliminary deferred tax liability recorded represents deferred tax liabilities assumed as part of the acquisition, net of deferred tax assets, related to net operating tax loss carryforwards of Crealta. Goodwill represents the excess of the preliminary acquisition consideration over the estimated fair value of net assets acquired and was recorded in the condensed consolidated balance sheet as of the acquisition date. The Company does not expect any portion of this goodwill to be deductible for tax purposes. Hyperion Acquisition On May 7, 2015, the Company completed the acquisition of Hyperion in which it acquired all of the issued and outstanding shares of Hyperion’s common stock for $46.00 per share. The acquisition added two important medicines, RAVICTI and BUPHENYL, to the Company’s medicine portfolio. Through the acquisition, the Company leveraged as well as expanded the existing infrastructure of its orphan disease business. The total consideration for the acquisition was approximately $1.1 billion and was composed of the following (in thousands, except share and per share data): Fully diluted equity value (21,425,909 shares at $46.00 per share) $ 985,592 Net settlements on the exercise of stock options, restricted stock and performance stock units 89,806 Total consideration $ 1,075,398 During the three months ended March 31, 2016 and 2015, the Company incurred $0.7 million and $1.9 million, respectively, in Hyperion acquisition-related costs. The costs during the three months ended March 31, 2016 included consulting costs, lease termination charges and other consulting fees, and were accounted for as “general and administrative” expenses in the condensed consolidated statement of comprehensive loss. Pursuant to ASC 805, the Company accounted for the Hyperion acquisition as a business combination using the acquisition method of accounting. Identifiable assets and liabilities of Hyperion, including identifiable intangible assets, were recorded based on their estimated fair values as of the date of the closing of the acquisition. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. Significant judgment was required in determining the estimated fair values of developed technology intangible assets and certain other assets and liabilities. Such a preliminary valuation required estimates and assumptions including, but not limited to, estimating future cash flows and direct costs in addition to developing the appropriate discount rates and current market profit margins. The Company’s management believes the fair values recognized for the assets acquired and the liabilities assumed are based on reasonable estimates and assumptions. Accordingly, the purchase price adjustments are preliminary and are subject to further adjustments as additional information becomes available and as additional analyses are performed, and such further adjustments may be material. The following table summarizes the preliminary fair values assigned to the assets acquired and the liabilities assumed by the Company (in thousands): (Liabilities assumed) and assets acquired: Allocation Deferred tax liability, net $ (262,732 ) Accounts payable (2,439 ) Accrued trade discounts and rebates (9,792 ) Accrued expenses (7,566 ) Contingent royalties (86,800 ) Cash and cash equivalents 53,037 Short-term investments 39,049 Long-term investments 25,574 Accounts receivable, net 11,858 Inventory 13,498 Prepaid expenses and other current assets 2,533 Property and equipment 1,044 Other non-current assets 123 Developed technology 1,044,200 Goodwill 253,811 Fair value of consideration paid $ 1,075,398 Inventories acquired included raw materials and finished goods. Inventories were recorded at their current fair values. The fair value of finished goods has been determined based on the estimated selling price, net of selling costs and a margin on the selling costs. The fair value of raw materials was estimated to equal the replacement cost. A step up in the value of inventory of $8.7 million was recorded in connection with the acquisition and has subsequently been fully recognized in the condensed consolidated statement of comprehensive loss. Other tangible assets and liabilities were valued at their respective carrying amounts as management believes that these amounts approximated their acquisition date fair values. Identifiable intangible assets and liabilities acquired include developed technology and contingent royalties. The preliminary fair values of the developed technology and contingent royalties represent preliminary valuations performed with the assistance of an independent appraisal firm based on management’s estimates, forecasted financial information and reasonable and supportable assumptions. Developed technology intangible assets reflect the estimated value of Hyperion’s rights to its currently marketed medicines, RAVICTI and BUPHENYL. The fair value of developed technology was determined using an income approach. The income approach explicitly recognizes that the fair value of an asset is premised upon the expected receipt of future economic benefits such as earnings and cash inflows based on current sales projections and estimated direct costs for Hyperion’s medicines. Indications of value were developed by discounting these benefits to their acquisition-date worth at a discount rate of 8.5% that reflected the then-current return requirements of the market. The fair value of the RAVICTI and BUPHENYL developed technologies were capitalized as of the Hyperion acquisition date and are subsequently being amortized over 11 and 7 years, respectively, which are the periods in which over 90% of the estimated cash flows are expected to be realized. The Company has assigned a preliminary fair value to a contingent liability for royalties potentially payable under previously existing agreements related to RAVICTI and BUPHENYL. The royalties are payable under the terms of an asset purchase agreement and an amended and restated collaboration agreement with Ucyclyd Pharma, Inc. (“Ucyclyd”) and a license agreement with Saul W. Brusilow, M.D. and Brusilow Enterprises Inc. (together “Brusilow”). See Note 12 for details of the percentages payable under such agreements. The initial fair value of this liability was $86.8 million and was determined using a discounted cash flow analysis incorporating the estimated future cash flows of royalty payments resulting from future sales. The discount rate used was the same as for the fair value of the developed technology. Deferred tax assets and liabilities arise from acquisition accounting adjustments where book values of certain assets and liabilities differ from their tax bases. Deferred tax assets and liabilities are recorded at the currently enacted rates which will be in effect at the time when the temporary differences are expected to reverse in the country where the underlying assets and liabilities are located. Hyperion’s developed technology as of the acquisition date was located primarily in the United States where a U.S. tax rate of 39% is being utilized and a significant deferred tax liability is recorded. Upon consummation of the Hyperion acquisition, Hyperion became a member of the Company’s U.S. tax consolidation group. As such, its tax assets and liabilities were considered in determining the appropriate amount (if any) of valuation allowances that should be recognized in assessing the realizability of the group’s deferred tax assets. The Hyperion acquisition adjustments resulted in the recognition of significant net deferred tax liabilities. Per ASC Topic 740, Accounting for Uncertainty in Income Taxes Short-term and long-term investments included in the table above represent available-for-sale securities that were reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. Available-for-sale investments were recorded at fair value and were liquidated shortly after the acquisition. Goodwill represents the excess of the preliminary acquisition consideration over the estimated fair value of net assets acquired and was recorded in the condensed consolidated balance sheet as of the acquisition date. The Company does not expect any portion of this goodwill to be deductible for tax purposes. Pro Forma Information The following table represents the condensed consolidated financial information for the Company for the three months ended March 31, 2015 on a pro forma basis, assuming that the Crealta and Hyperion acquisitions occurred as of January 1, 2015. The historical financial information has been adjusted to give effect to pro forma items that are directly attributable to the Crealta and Hyperion acquisitions, and are expected to have a continuing impact on the consolidated results. These items include, among others, adjustments to record the amortization of definite-lived intangible assets, interest expense, debt discount and deferred financing costs associated with the debt in connection with the acquisitions. The Company does not believe that the pre-acquisition operating results for Crealta during January 2016 are material to the combined entity and as such the Company did not prepare an unaudited pro forma combined statement of operations for the three months ended March 31, 2016. Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future (in thousands): For the Three Months Ended March 31, 2015 As reported Pro forma adjustments Pro forma Net sales $ 113,141 $ 40,613 $ 153,754 Net loss $ (19,553 ) $ (21,013 ) $ (40,566 ) The Company’s unaudited condensed consolidated statements of comprehensive loss for the three months ended March 31, 2016 include KRYSTEXXA and MIGERGOT net sales as a result of the acquisition of Crealta of $16.2 million and $0.9 million, respectively, and RAVICTI and BUPHENYL net sales as a result of the acquisition of Hyperion of $37.1 million and $3.7 million, respectively. Hyperion and

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventories	NOTE 4 – INVENTORIES Inventories are stated at the lower of cost or market value. Inventories consist of raw materials, work-in-process and finished goods. The Company has entered into manufacturing and supply agreements for the manufacture or purchase of raw materials and production supplies. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs. The components of inventories as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Raw materials $ 1,719 $ 6,232 Work-in-process 143,245 631 Finished goods 35,238 11,513 Inventories, net $ 180,202 $ 18,376 Work-in-progress and finished goods at March 31, 2016 included $135.5 million and $20.7 million, respectively, of stepped-up KRYSTEXXA and MIGERGOT inventory. During the three months ended March 31, 2016, the Company amortized $7.4 million of KRYSTEXXA and MIGERGOT inventory step-up.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	NOTE 5 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Medicine samples inventory $ 5,154 $ 4,697 Prepaid co-pay expenses 1,949 1,881 Prepaid software license fees 1,217 1,638 Other prepaid expenses 9,162 7,642 Prepaid expenses and other current assets $ 17,482 $ 15,858

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Machinery and equipment $ 2,834 $ 2,946 Computer equipment 2,797 2,514 Software 7,978 1,360 Leasehold improvements 6,788 1,966 Other 1,634 276 22,031 9,062 Less accumulated depreciation (4,693 ) (3,791 ) Construction in process 160 3,492 Software implementation in process 1,083 5,257 Property and equipment, net $ 18,581 $ 14,020 The Company capitalizes development costs associated with internal use software, including external direct costs of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are expensed as incurred. Software implementation in process as of March 31, 2016 and December 31, 2015 is related to new enterprise resource planning software being implemented by the Company. The software is being implemented on a phased basis starting January 2016 and depreciation is not recorded on capitalized costs relating to a phase which has not yet entered service. Once a particular phase of the project enters service, associated capitalized costs are moved from “software implementation in process” to “software” in the table above, and depreciation commences. Depreciation expense was $1.0 million and $0.7 million for the three months ended March 31, 2016 and 2015, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 7 – GOODWILL AND INTANGIBLE ASSETS Goodwill The gross carrying amount of goodwill as of March 31, 2016 was as follows (in thousands): Balance at December 31, 2015 $ 253,811 Acquired during the period 1,791 Balance at March 31, 2016 $ 255,602 In May 2015, the Company recognized goodwill with a preliminary value of $253.8 million in connection with the Hyperion acquisition, which represented the excess of the purchase price over the fair value of the net assets acquired. In January 2016, the Company recognized goodwill with a preliminary value of $1.8 million in connection with the Crealta acquisition, which represented the excess of the purchase price over the fair value of the net assets acquired. As of March 31, 2016, there were no accumulated goodwill impairment losses. Intangible Assets The Company’s intangible assets consist of developed technology related to ACTIMMUNE, PENNSAID 2%, RAYOS, VIMOVO, RAVICTI, BUPHENYL, KRYSTEXXA and MIGERGOT in the United States, and LODOTRA and AMMONAPS in Europe, as well as in-process research and development (“IPR&D”) and customer relationships for ACTIMMUNE. In May 2015, in connection with the acquisition of Hyperion, the Company capitalized $1,021.6 million of developed technology related to RAVICTI and $22.6 million of developed technology related to BUPHENYL. In January 2016, in connection with the acquisition of Crealta, the Company capitalized $392.7 million of developed technology related to KRYSTEXXA and $24.6 million of developed technology related to MIGERGOT. See Note 3 for further details of intangible assets acquired in business acquisitions. The Company tests its intangible assets for impairment when events or circumstances may indicate that the carrying value of these assets exceeds their fair value. The Company does not believe there have been any circumstances or events that would indicate that the carrying value of any of its intangible assets was impaired at March 31, 2016 or December 31, 2015. As of March 31, 2016 and December 31, 2015, amortizable intangible assets consisted of the following (in thousands): March 31, 2016 December 31, 2015 Cost Accumulated Amortization Net Book Value Cost Basis Accumulated Amortization Net Book Value Developed technology $ 2,209,795 $ (232,893 ) $ 1,976,902 $ 1,792,495 $ (183,446 ) $ 1,609,049 Customer relationships 8,100 (1,242 ) 6,858 8,100 (1,039 ) 7,061 Total amortizable intangible assets $ 2,217,895 $ (234,135 ) $ 1,983,760 $ 1,800,595 $ (184,485 ) $ 1,616,110 IPR&D is not amortized until successful completion of the project. IPR&D assets represent capitalized incomplete research projects related to ACTIMMUNE that the Company acquired through a business combination. Amortization expense for the three months ended March 31, 2016 and 2015 was $49.7 million and $17.7 million, respectively. As of March 31, 2016, estimated future amortization expense was as follows (in thousands): 2016 (April to December) $ 152,134 2017 202,946 2018 202,946 2019 189,953 2020 189,735 Thereafter 1,046,046 Total $ 1,983,760

Accrued Trade Discounts and Reb

Accrued Trade Discounts and Rebates	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Accrued Trade Discounts and Rebates	NOTE 8 – ACCRUED TRADE DISCOUNTS AND REBATES Accrued trade discounts and rebates as of , 2015 (in thousands): March 31, 2016 December 31, 2015 Accrued wholesaler fees and commercial rebates $ 24,482 $ 21,112 Accrued co-pay and other patient assistance 126,255 114,201 Accrued government rebates and chargebacks 73,633 48,456 Accrued trade discounts and rebates $ 224,370 $ 183,769 Invoiced wholesaler fees and commercial rebates, co-pay and other patient assistance, and government rebates and chargebacks in accounts payable 45,263 — Total customer-related accruals and allowances $ 269,633 $ 183,769 The following table summarizes changes in the Company’s customer-related accruals and allowances from December 31, 2015 to March 31, 2016 (in thousands): Wholesaler Fees Co-Pay and Government and Commercial Other Patient Rebates and Rebates Assistance Chargebacks Total Balance at December 31, 2015 $ 21,112 $ 114,201 $ 48,456 $ 183,769 Current provisions relating to sales in the three months ended March 31, 2016 25,480 388,552 60,286 474,318 Adjustments relating to prior year sales 2,956 — (2,282 ) 674 Payments relating to sales in the three months ended March 31, 2016 (7,194 ) (224,243 ) (17,037 ) (248,474 ) Payments relating to sales in prior years (18,334 ) (114,189 ) (9,555 ) (142,078 ) Crealta acquisition on January 13, 2016 492 — 932 1,424 Balance at March 31, 2016 $ 24,512 $ 164,321 $ 80,800 $ 269,633

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2016
Payables And Accruals [Abstract]
Accrued Expenses	NOTE 9 – ACCRUED EXPENSES Accrued expenses as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Payroll-related expenses $ 33,790 $ 47,205 Consulting and professional services 12,483 17,160 Accrued interest 16,187 10,637 Accrued other 26,680 25,044 Accrued expenses $ 89,140 $ 100,046 Accrued payroll-related expenses at March 31, 2016 include $5.4 million and $3.2 million relating to severance and related employee costs as a result of the Hyperion and Crealta acquisitions, respectively. The Company anticipates that a significant amount of Hyperion and Crealta acquisition-related accrued expenses will be paid by the end of the second quarter of 2016 and the first quarter of 2017, respectively.

Accrued Royalties

Accrued Royalties	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Accrued Royalties	NOTE 10 – ACCRUED ROYALTIES Changes in the liability for royalties during the three months ended March 31, 2016 consisted of the following (in thousands): Balance as of December 31, 2015 $ 175,219 Assumed KRYSTEXXA and MIGERGOT accrued royalties 99 Assumed KRYSTEXXA and MIGERGOT contingent royalty liabilities 51,300 Royalty payments (8,944 ) Accretion expense 9,359 Balance as of March 31, 2016 227,033 Less: Current portion (54,588 ) Accrued royalties, net of current $ 172,445 The Company did not record any remeasurements of contingent royalty liabilities during the three months ended March 31, 2016, as there were no triggering events during the period.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 11 – FAIR VALUE MEASUREMENTS The following tables and paragraphs set forth the Company’s financial instruments that are measured at fair value on a recurring basis within the fair value hierarchy. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The following describes three levels of inputs that may be used to measure fair value: Level 1 —Observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2 —Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3 —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company utilizes the market approach to measure fair value for its money market funds. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. As of March 31, 2016, the Company’s restricted cash included bank time deposits which were measured at fair value using Level 2 inputs and their carrying values were approximately equal to their fair values. Level 2 inputs, obtained from various third-party data providers, represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. There were no transfers between the different levels of the fair value hierarchy in 2016 or 2015. Assets and liabilities measured at fair value on a recurring basis The following table sets forth the Company’s financial assets and liabilities at fair value on a recurring basis as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 Level 1 Level 2 Level 3 Total Assets: Bank time deposits $ — $ 1,500 $ — $ 1,500 Money market funds 210,280 — — 210,280 Total assets at fair value $ 210,280 $ 1,500 $ — $ 211,780 December 31, 2015 Level 1 Level 2 Level 3 Total Assets: Bank time deposits $ — $ 1,000 $ — $ 1,000 Money market funds 280,053 — — 280,053 Total assets at fair value $ 280,053 $ 1,000 $ — $ 281,053

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 12 – COMMITMENTS AND CONTINGENCIES Lease Obligations The Company has the following lease agreements in place for real properties: Location Approximate Square Footage Lease Expiry Date Dublin, Ireland 18,900 November 4, 2029 Lake Forest, Illinois (1) 160,000 March 31, 2024 Deerfield, Illinois (2) 53,500 June 30, 2018 Brisbane, California (3) 20,100 November 30, 2019 Mannheim, Germany 9,500 December 31, 2016 Chicago, Illinois 6,500 December 31, 2018 Roswell, Georgia 6,200 October 31, 2018 Reinach, Switzerland 3,500 May 31, 2020 (1) In connection with the Lake Forest, Illinois lease, the Company has provided a $2.0 million letter of credit to the landlord, through a commercial bank. The Company has two separate lease agreements in place for this property, one of which, consisting of approximately 15,000 square feet, was assumed by the Company as a result of its acquisition of Crealta in January 2016 and will expire on October 31, 2017. (2) The Company vacated the premises in Deerfield, Illinois in January 2016. (3) The Company vacated the premises in Brisbane, California in December 2015 and entered into a sublease agreement for the property with a third party. Purchase Commitments In August 2007, the Company entered into a manufacturing and supply agreement with Jagotec AG (“Jagotec”). Under the agreement, Jagotec or its affiliates are required to manufacture and supply RAYOS/LODOTRA exclusively to the Company in bulk. The Company committed to a minimum purchase of RAYOS/LODOTRA tablets from Jagotec for five years from the date of first launch of RAYOS/LODOTRA in a major country, as defined in the agreement, which was April 2009. Thereafter, the agreement automatically renews on a yearly basis until either party provides two years advance written notice of termination. In April 2016 the agreement automatically renewed, therefore the earliest the agreement can expire according to this advance notice procedure is April 15, 2019, and the minimum purchase commitment is in force until April 2019. At March 31, 2016, the minimum purchase commitment based on tablet pricing in effect under the agreement was $2.6 million through April 2019. In May 2011, the Company entered into a manufacturing and supply agreement with Sanofi-Aventis U.S. LLC (“Sanofi-Aventis U.S.”), and amended the agreement effective as of September 25, 2013. Pursuant to the agreement, as amended, Sanofi-Aventis U.S. is obligated to manufacture and supply DUEXIS to the Company in final, packaged form, and the Company is obligated to purchase DUEXIS exclusively from Sanofi-Aventis U.S. for the commercial requirements of DUEXIS in North America, South America and certain countries and territories in Europe, including the European Union (“EU”) member states and Scandinavia. At March 31, 2016, the Company had a binding purchase commitment to Sanofi-Aventis U.S. for DUEXIS of $8.9 million, which is to be delivered through June 2016. In July 2013, Vidara and Boehringer Ingelheim RCV GmbH & Co. KG (“Boehringer Ingelheim”) entered into an exclusive supply agreement, which the Company assumed as a result of the Vidara Merger. Under the agreement, Boehringer Ingelheim is required to manufacture and supply interferon gamma-1 b (ACTIMMUNE) to the Company. The Company is required to purchase minimum quantities of finished medicine per annum through July 2020. As of March 31, 2016, the minimum binding purchase commitment to Boehringer Ingelheim was $15.9 million (converted using a Dollar-to-Euro exchange rate of 1.1381) through July 2020. In November 2013, the Company entered into a long-term master manufacturing services and product agreement with Patheon Pharmaceuticals Inc. (“Patheon”) pursuant to which Patheon is obligated to manufacture VIMOVO for the Company through December 31, 2019. The Company agreed to purchase a specified percentage of VIMOVO requirements for the United States from Patheon. The Company must pay an agreed price for final, packaged VIMOVO supplied by Patheon as set forth in the Patheon manufacturing agreement, subject to adjustments, including certain unilateral adjustments by Patheon, such as annual adjustments for inflation and adjustments to account for certain increases in the cost of components of VIMOVO other than active materials. The Company issues 12-month forecasts of the volume of VIMOVO that the Company expects to order. The first six months of the forecast are considered binding firm orders. At March 31, 2016, the Company had a binding purchase commitment with Patheon for VIMOVO of $3.7 million through May 2016. In October 2014, in connection with the acquisition of the U.S. rights to PENNSAID 2% from Nuvo, the Company and Nuvo entered into an exclusive supply agreement, which was amended in February 2016. Under the supply agreement, Nuvo is obligated to manufacture and supply PENNSAID 2% to the Company. The term of the supply agreement is through December 31, 2029, but the agreement may be terminated earlier by either party for any uncured material breach by the other party of its obligations under the supply agreement or upon the bankruptcy or similar proceeding of the other party. At least 90 days prior to the first day of each calendar month during the term of the supply agreement, the Company submits a binding written purchase order to Nuvo for PENNSAID 2% in minimum batch quantities. At March 31, 2016, the Company had a binding purchase commitment with Nuvo for PENNSAID 2% of $9.1 million through June 2016. Purchase orders relating to the manufacture of RAVICTI and BUPHENYL of $5.0 million were outstanding at March 31, 2016. In addition to these purchase orders, the Company’s manufacturing agreement with Lyne Laboratories Inc. in relation to RAVICTI provides for a minimum purchase amount of $0.5 million for 2016. In March 2007, Savient Pharmaceuticals, Inc. (as predecessor in interest in Crealta), entered into a commercial supply agreement with Bio-Technology General (Israel) Ltd (“BTG Israel) for the production of the bulk KRYSTEXXA medicine (“bulk medicine”). The Company assumed this agreement as part of the Crealta acquisition. Under this agreement, the Company is obligated to purchase at least 80 percent of its annual world-wide bulk medicine requirements from BTG Israel. In December 2015, Crealta received a notice of termination from BTG Israel and as a result the agreement will terminate on December 15, 2018. If the manufacture of the bulk medicine is moved out of Israel, the Company may be required to obtain the approval of the Israeli Office of the Chief Scientist (“OCS”) because certain KRYSTEXXA intellectual property was initially developed with a grant funded by the OCS. In addition, if the manufacturing is moved out of Israel, the Company may be required to pay the OCS additional amounts as a repayment for the OCS grant funding. As of the Crealta acquisition date it was probable that the manufacture of the KRYSTEXXA bulk medicine would be moved outside of Israel and the Company may be required to pay additional amounts estimated at approximately $6.9 million. The estimated obligation was recorded as an assumed contingent liability as of the Crealta acquisition date (see Note 3 for further details) and is included in “other long-term liabilities” in the condensed consolidated balance sheet. The Company issues 18-month forecasts of the volume of KRYSTEXXA that the Company expects to order. The first six months of the forecast are considered binding firm orders. At March 31, 2016, the Company had a binding purchase commitment with BTG Israel for KRYSTEXXA of $2.5 million through June 2016. Royalty Agreements RAYOS/LODOTRA In connection with an August 2004 development and license agreement with SkyePharma AG (“SkyePharma”) and Jagotec, a wholly-owned subsidiary of SkyePharma, regarding certain proprietary technology and know-how owned by SkyePharma, Jagotec is entitled to receive a single digit percentage royalty on net sales of RAYOS/LODOTRA and on any sub-licensing income, which includes any payments not calculated based on the net sales of RAYOS/LODOTRA, such as license fees, lump sums and milestone payments. VIMOVO The Company entered into a license agreement with Pozen Inc., who subsequently entered into a business combination with Tribute Pharmaceuticals Canada Inc. to become known as Aralez Pharmaceuticals Inc. (“Aralez”). Under this agreement, the Company is required to pay Aralez a flat 10% royalty on net sales of VIMOVO and other medicines sold by the Company, its affiliates or sublicensees during the royalty term that contain gastroprotective agents in a single fixed combination oral solid dosage form with nonsteroidal anti-inflammatory drugs, subject to minimum annual royalty obligations of $7.5 million. These minimum royalty obligations will continue for each year during which one of Aralez’s patents covers such medicines in the United States and there are no competing medicines in the United States. The royalty rate may be reduced to a mid-single digit royalty rate as a result of loss of market share to competing medicines. The Company’s obligation to pay royalties to Aralez will expire upon the later of (a) expiration of the last-to-expire of certain patents covering such medicines in the United States, and (b) ten years after the first commercial sale of such medicines in the United States. ACTIMMUNE Under a license agreement, as amended, with Genentech Inc. (“ · Through November 25, 2014, a royalty of 45% of the first $3.7 million in net sales achieved in a calendar year, and 10% on all additional net sales in that year; · For the period from November 26, 2014 through May 5, 2018, a royalty in the 20% to 30% range for the first tier in net sales and in the 1% to 9% range for the second tier; and · From May 6, 2018 and for so long as the Company continues to commercially sell ACTIMMUNE, an annual royalty in the low single digits as a percentage of annual net sales. Under the terms of an assignment and option agreement with Connetics, the Company is obligated to pay royalties to Connetics on the Company’s net sales of ACTIMMUNE as follows: · 0.25% of net sales of ACTIMMUNE, rising to 0.5% once cumulative net sales of ACTIMMUNE in the United States surpass $1.0 billion; and in the event the Company develops and receives regulatory approval for ACTIMMUNE in the indication of scleroderma, the Company will be obligated to pay a royalty of 4% on all net sales of ACTIMMUNE recorded for use in that indication. RAVICTI Under the terms of an asset purchase agreement with Ucyclyd, the Company is obligated to pay to Ucyclyd tiered mid to high single-digit royalties on its global net sales of RAVICTI. Under the terms of a license agreement with Brusilow, BUPHENYL Under the terms of an amended and restated collaboration agreement with Ucyclyd, the Company is obligated to pay to Ucyclyd tiered mid to high single-digit royalties on its net sales in the United States of BUPHENYL to urea cycle disorder patients outside of the U.S. Food and Drug Administration (“FDA”) approved labeled age range for RAVICTI. KRYSTEXXA Under the terms of a license agreement with Duke and MVP, the Company is obligated to pay Duke a mid-single digit royalty on its global net sales of KRYSTEXXA and a low-double digit royalty on any global sublicense revenue. The Company is also obligated to pay MVP a mid-single digit royalty on its net sales of KRYSTEXXA outside of the United States and a low-double digit to royalty on any sublicense revenue outside of the United States. The royalty obligations described above are included in accrued royalties on the Company’s condensed consolidated balance sheets. Total royalty-related expenses recognized in cost of goods sold for the three months ended March 31, 2016 and 2015 was $10.5 million and $3.6 million, respectively. Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. In addition, the Company from time to time has billing disputes with vendors in which amounts invoiced are not in accordance with the terms of their contracts. In November 2015, Express Scripts, Inc. (“Express Scripts”) filed suit against the Company in Delaware Superior Court, Newcastle County, asserting claims for breach of contract, breach of the implied covenant of good faith and fair dealing, unjust enrichment and declaratory relief arising from the parties’ 2012 Preferred Savings Grid Rebate Program Agreement. In its complaint, Express Scripts seeks damages of $139.9 million for alleged unpaid rebates and administrative fees as of October 1, 2015, additional potential rebates and administrative fees through the end of 2015, late fees, interest and attorneys’ fees and costs. On January 11, 2016, the Company answered the complaint, denying Express Scripts’ claims and denying that it owes Express Scripts any damages or other relief. The Company also filed a counter-claim against Express Scripts for breach of contract, breach of the implied covenant of good faith and fair dealing and declaratory relief arising from Express Scripts’ breach of the rebate agreement. On February 1, 2016, Express Scripts filed an answer to the Company’s counter-claim. The parties have commenced discovery and a bench trial in the case is currently scheduled for April 2017. Consistent with FAS 5, Accounting for Contingencies In November 2015, the Company received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information related to its patient access programs and other aspects of its marketing and commercialization activities. The Company is unable to predict how long this investigation will continue or its outcome, but it anticipates that it may incur significant costs in connection with the investigation, regardless of the outcome. The Company may also become subject to similar investigations by other governmental agencies. The investigation by the U.S. Attorney’s Office and any additional investigations of the Company’s patient access programs and sales and marketing activities may result in damages, fines, penalties or other administrative sanctions against the Company. Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. In accordance with its memorandum and articles of association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. Additionally, the Company has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers. These agreements, among other things, require the Company to indemnify its directors and executive officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of the Company’s directors or executive officers, or any of the Company’s subsidiaries or any other company or enterprise to which the person provides services at the Company’s request. There have been no claims to date and the Company has a director and officer insurance policy that enables it to recover a portion of any amounts paid for future potential claims. Certain of the Company’s officers and directors had also entered into separate indemnification agreements with HPI prior to the Vidara Merger.

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	NOTE 13 – LEGAL PROCEEDINGS On July 15, 2013, the Company received a Paragraph IV Patent Certification from Watson Laboratories, Inc.—Florida, known as Actavis Laboratories FL, Inc. (“Actavis FL”), advising that Actavis FL had filed an Abbreviated New Drug Application (“ANDA”) with the FDA for a generic version of RAYOS, containing up to 5 mg of prednisone. On August 26, 2013, the Company, together with Jagotec, filed suit in the United States District Court for the District of New Jersey against Actavis FL, Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. seeking an injunction to prevent the approval of the ANDA. On October 1, 2015, the Company’s subsidiary Horizon Pharma Switzerland GmbH, as well as Jagotec, entered into a license and settlement agreement (the “Actavis settlement agreement”) with Actavis FL relating to the Company’s and Jagotec’s on-going patent infringement litigation. In accordance with legal requirements, the Company, Jagotec and Actavis FL have agreed to submit the Actavis settlement agreement to the U.S. Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) for review. The parties have submitted the Actavis settlement agreement to the FTC and DOJ for review and no issues were raised by either. The parties agreed to file stipulations of dismissal with the court regarding the litigation and the court entered the stipulation and closed the case on December 4, 2015. The Actavis settlement agreement provides for a full settlement and release by each party of all claims that relate to the litigation or under the patents with respect to Actavis FL’s generic version of RAYOS tablets. Under the Actavis settlement agreement, the Company and Jagotec granted Actavis FL a non-exclusive license to manufacture and commercialize Actavis FL’s generic version of RAYOS tablets in the United States after the generic entry date (as defined below) and to take steps necessary to develop inventory of, and prepare to commercialize, Actavis FL’s generic version of RAYOS tablets during certain limited periods prior to the generic entry date. The Company and Jagotec also agreed that during the 180 days after the Generic Entry Date, the license granted to Actavis FL would be exclusive with respect to any third-party generic version of RAYOS tablets. Under the Actavis settlement agreement, the generic entry date is December 23, 2022; however, Actavis FL may be able to enter the market earlier under certain circumstances. Such events relate to the resolution of any other third-party RAYOS patent litigation, the entry of other generic versions of RAYOS tablets or certain substantial reductions in RAYOS prescriptions over specified periods of time. The Company and Jagotec also agreed not to sue or assert any claim against Actavis FL for infringement of any patent or patent application owned or controlled by the Company or Jagotec during the term of the Actavis settlement agreement based on Actavis FL’s generic version of RAYOS tablets in the United States. In turn, Actavis FL agreed not to challenge the validity or enforceability of the licensed patents. If the Company or Jagotec enter into any similar agreements with other parties with respect to generic versions of RAYOS tablets, they agreed to amend the Actavis settlement agreement to provide Actavis FL with terms that are no less favorable than those provided to the other parties with respect to the license terms, generic entry date, permitted pre-market activities and notice provisions. On November 13, 2014, the Company received a Paragraph IV Patent Certification from Watson Laboratories, Inc. (“Watson Laboratories”) advising that Watson Laboratories had filed an ANDA with the FDA for a generic version of PENNSAID 2%. On December 23, 2014, the Company filed suit in the United States District Court for the District of New Jersey against Watson Laboratories, Actavis, Inc., and Actavis plc (collectively “Actavis”) seeking an injunction to prevent the approval of the ANDA. Since then, Watson Laboratories, Inc. changed its name to Actavis Laboratories UT, Inc., and remains the current holder of the ANDA. The lawsuit alleges that Actavis has infringed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, and 8,871,809 by filing an ANDA seeking approval from the FDA to market generic versions of PENNSAID 2% prior to the expiration of the patents. The subject patents are listed in the FDA’s Orange Book (“Orange Book”). The commencement of the patent infringement lawsuit stays, or bars, FDA approval of Actavis’ ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or are invalid. The court has not yet set a trial date for the Actavis action. On June 30, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Actavis for patent infringement of U.S. Patent No. 9,066,913. On August 11, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Actavis for patent infringement of U.S. Patent No. 9,101,591. On September 17, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Actavis for patent infringement of U.S. Patent No. 9,132,110. All three patents, U.S. Patent Nos. 9,066,913, 9,101,591, and 9,132,110 are listed in the Orange Book and have claims that cover PENNSAID 2%. These three cases have since been consolidated with the case filed against Actavis on December 23, 2014. On October 27, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Actavis for patent infringement of U.S. Patent Nos. 9,168,304 and 9,168,305. On February 5, 2016, the Company filed suit in the United States District Court for the District of New Jersey against Actavis for patent infringement of U.S. Patent No. 9,220,784. All three patents, U.S. Patent Nos. 9,168,304, 9,168,305, and 9,220,784 are listed in the Orange Book and have claims that cover PENNSAID 2%. On December 2, 2014, the Company received a Paragraph IV Patent Certification against Orange Book listed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, and 8,741,956 from Paddock Laboratories, LLC (“Paddock”) advising that Paddock had filed an ANDA with the FDA for a generic version of PENNSAID 2%. On January 9, 2015, the Company received from Paddock another Paragraph IV Patent Certification against newly Orange Book listed U.S. Patent No. 8,871,809. On January 13, 2015 and January 14, 2015, the Company filed suits in the United States District Court for the District of New Jersey and the United States District Court for the District of Delaware, respectively, against Paddock seeking an injunction to prevent the approval of the ANDA. The lawsuits alleged that Paddock has infringed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, and 8,871,809 by filing an ANDA seeking approval from the FDA to market generic versions of PENNSAID 2% prior to the expiration of the patents. On May 6, 2015, the Company entered into a settlement and license agreement (the “Perrigo settlement agreement”) with Perrigo Company plc and its subsidiary Paddock (collectively, “Perrigo”), relating to the Company’s on-going patent infringement litigation. The Perrigo settlement agreement provides for a full settlement and release by both the Company and Perrigo of all claims that were or could have been asserted in the litigation and that arise out of the issues that were the subject of the litigation or Perrigo’s generic version of PENNSAID 2%. Under the Perrigo settlement agreement, the Company granted Perrigo a non-exclusive license to manufacture and commercialize Perrigo’s generic version of PENNSAID 2% in the United States after the license effective date (as defined below) and to take steps necessary to develop inventory of, and prepare to commercialize, Perrigo’s generic version of PENNSAID 2% during certain limited periods prior to the license effective date. Under the Perrigo settlement agreement, the license effective date is January 10, 2029; however, Perrigo may be able to enter the market earlier under certain circumstances. Such events relate to the resolution of any other third-party PENNSAID 2% patent litigation, the entry of other third-party generic versions of PENNSAID 2% or certain substantial reductions in the Company’s PENNSAID 2% shipments over specified periods of time. Under the Perrigo settlement agreement, the Company also agreed not to sue or assert any claim against Perrigo for infringement of any patent or patent application owned or controlled by the Company during the term of the Perrigo settlement agreement based on the manufacture, use, sale, offer for sale, or importation of Perrigo’s generic version of PENNSAID 2% in the United States. In certain circumstances following the entry of other third-party generic versions of PENNSAID 2%, the Company may be required to supply Perrigo PENNSAID 2% as its authorized distributor of generic PENNSAID 2%, with the Company receiving specified percentages of any net sales by Perrigo. The Company also agreed that if it enters into any similar agreements with other parties with respect to generic versions of PENNSAID 2%, the Company will amend the Perrigo settlement agreement to provide Perrigo with terms that are no less favorable than those provided to the other parties. On February 2, 2015, the Company received a Paragraph IV Patent Certification against Orange Book listed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, 8,741,956, and 8,871,809 from Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (collectively, “Taro”) advising that Taro had filed an ANDA with the FDA for a generic version of PENNSAID 2%. On March 13, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Taro seeking an injunction to prevent the approval of the ANDA. On September 9, 2015, certain subsidiaries of the Company (the “Horizon Subsidiaries”) entered into a settlement and license agreement with Taro (the “Taro settlement agreement”) relating to the Horizon Subsidiaries’ on-going patent infringement litigation. In accordance with legal requirements, the Horizon Subsidiaries and Taro have submitted the Taro settlement agreement to the FTC and DOJ for review. The Horizon Subsidiaries and Taro have also filed stipulations of dismissal with the courts regarding the litigation. The Taro settlement agreement provides for a full settlement and release by both us and Taro of all claims that were or could have been asserted in the Litigation and that arise out of the issues that were subject of the litigation or Taro’s generic version of PENNSAID 2%. Under the Taro settlement agreement, the Horizon Subsidiaries granted Taro a non-exclusive license to manufacture and commercialize Taro’s generic version of PENNSAID 2% in the United States after the license effective date and to take steps necessary to develop inventory of, and prepare to commercialize, Taro’s generic version of PENNSAID 2% during certain limited periods prior to the license effective date. Under the Taro settlement agreement, the license effective date is January 10, 2029; however, Taro may be able to enter the market earlier under certain circumstances. Such events relate to the resolution of any other third-party PENNSAID 2% patent litigation, the entry of other third-party generic versions of PENNSAID 2% or certain substantial reductions in Horizon’s PENNSAID 2% shipments over specified periods of time. Under the Taro settlement agreement, the Horizon Subsidiaries also agreed not to sue or assert any claim against Taro for infringement of any patent or patent application owned or controlled by the Horizon Subsidiaries during the term of the Taro settlement agreement based on the manufacture, use, sale, offer for sale, or importation of Taro’s generic version of PENNSAID 2% in the United States. The Horizon Subsidiaries also agreed that if they enter into any similar agreements with other parties with respect to generic versions of PENNSAID 2%, they will amend the Taro settlement agreement to provide Taro with terms that are no less favorable than those provided to the other parties. On March 18, 2015, the Company received a Paragraph IV Patent Certification against Orange Book listed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, 8,741,956, and 8,871,809 from Lupin Limited advising that Lupin Limited had filed an ANDA with the FDA for generic version of PENNSAID 2%. On April 30, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Lupin Limited and Lupin Pharmaceuticals Inc. (collectively, “Lupin”), seeking an injunction to prevent the approval of the ANDA. The lawsuit alleges that Lupin has infringed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, and 8,871,809 by filing an ANDA seeking approval from the FDA to market generic versions of PENNSAID 2% prior to the expiration of the patents. The subject patents are listed in the Orange Book. The commencement of the patent infringement lawsuit stays, or bars, FDA approval of Lupin’s ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or are invalid. The court has not yet set a trial date for the Lupin action. On June 30, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Lupin for patent infringement of U.S. Patent No. 9,066,913. On August 11, 2015, the Company filed an amended complaint in the United States District Court for the District of New Jersey against Lupin that added U.S. Patent No. 9,101,591 to the litigation with respect to U.S. Patent No. 9,066,913. On September 17, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Lupin for patent infringement of U.S. Patent No. 9,132,110. All three patents, U.S. Patent Nos. 9,066,913, 9,101,591, and 9,132,110 are listed in the Orange Book and have claims that cover PENNSAID 2%. On October 27, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Lupin for patent infringement of U.S. Patent Nos. 9,168,304 and 9,168,305. On February 5, 2016, the Company filed suit in the United States District Court for the District of New Jersey against Lupin for patent infringement of U.S. Patent No. 9,220,784. All three patents, U.S. Patent Nos. 9,168,304, 9,168,305, and 9,220,784 are listed in the Orange Book and have claims that cover PENNSAID 2%. The Company received from Teligent, Inc., formerly known as IGI Laboratories, Inc. (“Teligent”), a Paragraph IV Patent Certification dated March 24, 2015 against Orange Book listed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, 8,741,956, and 8,871,809 advising that Teligent had filed an ANDA with the FDA for a generic version of PENNSAID 2%. On May 21, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Teligent seeking an injunction to prevent the approval of the ANDA. The lawsuit alleges that Teligent has infringed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, and 8,871,809 by filing an ANDA seeking approval from the FDA to market generic versions of PENNSAID 2% prior to the expiration of the patents. The subject patents are listed in the Orange Book. The commencement of the patent infringement lawsuit stays, or bars, FDA approval of Teligent’s ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or are invalid. The court has not yet set a trial date for the Teligent action. On June 30, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Teligent for patent infringement of U.S. Patent No. 9,066,913. On August 11, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Teligent for patent infringement of U.S. Patent No. 9,101,591. On September 17, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Teligent for patent infringement of U.S. Patent No. 9,132,110. All three patents, U.S. Patent Nos. 9,066,913, 9,101,591, and 9,132,110 are listed in the Orange Book and have claims that cover PENNSAID 2%. On October 27, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Teligent for patent infringement of U.S. Patent Nos. 9,168,304 and 9,168,305. On February 5, 2016, the Company filed suit in the United States District Court for the District of New Jersey against Teligent for patent infringement of U.S. Patent No. 9,220,784. All three patents, U.S. Patent Nos. 9,168,304, 9,168,305, and 9,220,784 are listed in the Orange Book and have claims that cover PENNSAID 2%. On May 2, 2016, our on-going patent infringement litigation with Teligent was dismissed without prejudice after the filing of a joint stipulation of dismissal by the parties. The Company received from Amneal Pharmaceuticals LLC (“Amneal”) a Paragraph IV Patent Certification dated April 2, 2015 against Orange Book listed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, 8,741,956, and 8,871,809 advising that Amneal had filed an ANDA with the FDA for a generic version of PENNSAID 2%. On May 15, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Amneal seeking an injunction to prevent the approval of the ANDA. The lawsuit alleges that Amneal has infringed U.S. Patent Nos. 8,217,078, 8,252,838, 8,546,450, 8,563,613, 8,618,164, and 8,871,809 by filing an ANDA seeking approval from the FDA to market generic versions of PENNSAID 2% prior to the expiration of the patents. The subject patents are listed in the Orange Book. The commencement of the patent infringement lawsuit stays, or bars, FDA approval of Amneal’s ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or are invalid. The court has not yet set a trial date for the Amneal action. On June 30, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Amneal for patent infringement of U.S. Patent No. 9,066,913. On August 11, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Amneal for patent infringement of U.S. Patent No. 9,101,591. On September 17, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Amneal for patent infringement of U.S. Patent No. 9,132,110. All three patents, U.S. Patent Nos. 9,066,913, 9,101,591, and 9,132,110 are listed in the Orange Book and have claims that cover PENNSAID 2%. On October 27, 2015, the Company filed suit in the United States District Court for the District of New Jersey against Amneal for patent infringement of U.S. Patent Nos. 9,168,304 and 9,168,305. On February 5, 2016, the Company filed suit in the United States District Court for the District of New Jersey against Amneal for patent infringement of U.S. Patent No. 9,220,784. All three patents, U.S. Patent Nos. 9,168,304, 9,168,305, and 9,220,784 are listed in the Orange Book and have claims that cover PENNSAID 2%. On April 18, 2016, the Company entered into a settlement and license agreement (the “Amneal settlement agreement”) with Amneal relating to the Company’s on-going patent infringement litigation. In accordance with legal requirements, the Company and Amneal submitted the Amneal settlement agreement to the FTC and DOJ for review. The Company and Amneal have also agreed to file a stipulation of dismissal with the court regarding the litigation. The Amneal settlement agreement provides for a full settlement and release by both the Company and Amneal of all claims that were or could have been asserted in the litigation and that arise out of the issues that were the subject of the litigation or Amneal’s generic version of PENNSAID 2%. Under the Amneal settlement agreement, the Company granted Amneal a non-exclusive license to manufacture and commercialize Amneal’s generic version of PENNSAID 2% in the United States after the license effective date (as defined below) and to take steps necessary to develop inventory of, and prepare to commercialize, Amneal’s generic version of PENNSAID 2% during certain limited periods prior to the license effective date. Under the Amneal settlement agreement, the license effective date is January 10, 2029; however, Amneal may be able to enter the market earlier under certain circumstances. Such events relate to the resolution of any other third-party PENNSAID 2% patent litigation or the entry of other third-party generic versions of PENNSAID 2%. Under the Amneal settlement agreement, the Company also agreed not to sue or assert any claim against Amneal for infringement of any patent or patent application owned or controlled by the Company during the term of the Amneal settlement agreement based on the manufacture, use, sale, offer for sale, or importation of Amneal’s generic version of PENNSAID 2% in the United States. In certain circumstances following the entry of other third-party generic versions of PENNSAID 2%, the Company may be required to supply Amneal PENNSAID 2% as a non-exclusive, authorized distributor of generic PENNSAID 2%, with the Company receiving specified percentages of any net sales by Amneal. The Company also agreed that if it enters into any similar agreements with other parties with respect to generic versions of PENNSAID 2%, the Company will amend the Amneal settlement agreement to provide Amneal with terms that are no less favorable than those provided to the other parties. Currently, patent litigation is pending in the United States District Court for the District of New Jersey against four generic companies intending to market VIMOVO before the expiration of patents listed in the Orange Book. These cases are in the United States District Court for the District of New Jersey. They are collectively known as the VIMOVO cases, and involve the following sets of defendants: (i) Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. (collectively, “Dr. Reddy’s”); (ii) Lupin; (iii) Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, and Mylan Inc. (collectively, “Mylan”); and (iv) Actavis FL and Actavis Pharma, Inc. (collectively, “Actavis Pharma”). Patent litigation in the United States District Court for the District of New Jersey against a fifth generic company, Anchen Pharmaceuticals Inc. (“Anchen”), was dismissed on June 9, 2014 after Anchen recertified under Paragraph III. The Company understands that Dr. Reddy’s has entered into a settlement with AstraZeneca with respect to patent rights directed to Nexium for the commercialization of VIMOVO, and that according to the settlement agreement, Dr. Reddy’s is now able to commercialize VIMOVO under AstraZeneca’s Nexium patent rights. The settlement agreement, however, has no effect on the Aralez VIMOVO patents, which are still the subject of patent litigations. As part of the Company’s acquisition of the U.S. rights to VIMOVO, the Company has taken over and is responsible for the patent litigations that include the Aralez patents licensed to the Company under the amended and restated collaboration and license agreement for the United States with Aralez. The VIMOVO cases were filed on April 21, 2011, July 25, 2011, October 28, 2011, January 4, 2013, May 10, 2013, June 28, 2013, October 23, 2013, May 13, 2015 and November 24, 2015 and collectively include allegations of infringement of U.S. Patent Nos. 6,926,907, 8,557,285, 8,852,636, and 8,858,996. On June 18, 2015, the Company amended the complaints to add a charge of infringement of U.S. Patent No. 8,865,190. On January 7, 2016, Actavis asserted a counterclaim for declaratory judgment of invalidity and non-infringement of U.S. Patent No. 8,945,621. On January 25, 2016, the Company filed a new case against Actavis Pharma including allegations of infringement of U.S. Patent Nos. 9,161,920 and 9,198,888. This case was subsequently consolidated with the Actavis case involving U.S. Patent Nos. 8,852,636, 8,858,996, and 8,865,190. On February 10, 2016, the Company amended the complaints against Dr. Reddy’s, Lupin, and Mylan to add charges of infringement of U.S. Patent Nos. 9,161,920 and 9,198,888. On February 19, 2016, Mylan asserted a counterclaim for declaratory judgment of invalidity and non-infringement of U.S. Patent. No. 9,220,698. The cases asserting U.S. Patent Nos. 8,557,285 and 6,926,907 have been consolidated for discovery. The court has issued a claims construction order for these cases and has set a pretrial schedule, but has not yet set a trial date. The cases asserting U.S. Patent Nos. 8,852,636, 8,858,996, 8,865,190, 9,161,920 and 9,198,888 have been consolidated for discovery. The court has not issued a claims construction order or set a pretrial schedule. The Company understands the cases arise from Paragraph IV Patent Certification notice letters providing notice of the filing of ANDAs with the FDA seeking regulatory approval to market generic versions of VIMOVO before the expiration of the patents-in-suit. The Company understands the Dr. Reddy’s notice letters were dated March 11, 2011, November 20, 2012 and April 20, 2015; the Lupin notice letters were dated June 10, 2011 and March 12, 2014; the Mylan notice letters were dated May 16, 2013, February 9, 2015, January 26, 2016 and February 26, 2016; the Actavis Pharma notice letters were dated March 29, 2013, November 5, 2013, October 9, 2015, December 10, 2015, March 1, 2016 and April 6, 2016; and the Anchen notice letter was dated September 16, 2011. On February 24, 2015, Dr. Reddy’s Laboratories, Inc. filed a Petition for inter partes review (“IPR”) of U.S. Patent No. 8,557,285, one of the patents in litigation in the above referenced VIMOVO cases. On October 9, 2015, the United States Patent and Trademark Office (the “U.S. PTO”) denied such Petition for IPR. On May 21, 2015, the Coalition for Affordable Drugs VII LLC (“Coalition for Affordable Drugs”) filed a Petition for IPR of U.S. Patent No. 6,926,907, one of the patents in litigation in the above referenced VIMOVO cases. On December 8, 2015, the U.S. PTO denied such Petition for IPR. On June 5, 2015, the Coalition for Affordable Drugs filed another Petition for IPR of U.S. Patent No. 8,858,996, one of the patents in litigation in the above referenced VIMOVO cases. On December 17, 2015, the U.S. PTO denied such Petition for IPR. On August 7, 2015, the Coalition for Affordable Drugs filed another Petition for IPR of U.S. Patent No. 8,852,636, one of the patents in litigation in the above referenced VIMOVO cases. On February 11, 2016, the U.S. PTO denied such Petition for IPR. On August 12, 2015, the Coalition for Affordable Drugs filed another Petition for IPR of U.S. Patent No. 8,945,621, one of the patents in litigation in the above referenced VIMOVO cases. On February 22, 2016, the Patent Trial and Appeal Board (the “PTAB”) issued a decision to institute the IPR. On August 19, 2015, Lupin filed Petitions for IPR of U.S. Patent Nos. 8,858,996, 8,852,636, and 8,865,190, all patents in litigation in the above referenced VIMOVO cases. On March 1, 2016, the PTAB issued decisions to institute the IPRs for U.S. Patent Nos. 8,858,996 and 8,865,190. Also on March 1, 2016, the PTAB denied the Petition for IPR for U.S. Patent No. 8,852,636. On March 17, 2014, Hyperion received notice from Par Pharmaceutical, Inc. (“Par Pharmaceutical”) that it had filed an ANDA with the FDA seeking approval for a generic version of the Company’s medicine RAVICTI. The ANDA contained a Paragraph IV Patent Certification alleging that two of the patents covering RAVICTI, U.S. Patent No. 8,404,215, titled “Methods of therapeutic monitoring of nitrogen scavenging drugs,” which expires in March 2032 (the “’215 patent”), and U.S. Patent No. 8,642,012, titled “Methods of treatment using ammonia scavenging drugs,” which expires in September 2030 (the “’012 patent”), are invalid and/or will not be infringed by Par Pharmaceutical’s manufacture, use or sale of the medicine for which the ANDA was submitted. Par Pharmaceutical did not challenge the validity, enforceability, or infringement of the Company’s primary composition of matter patent for RAVICTI, U.S. Patent No. 5,968,979 titled “Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkanoic acid useful in treatment of various disorders,” which would have expired on February 7, 2015, but as to which Hyperion was granted an interim term of extension until February 7, 2016 and to which the U.S. PTO has granted a final term extension of 1,267 days. Hyperion filed suit in the United States District Court for the Eastern District of Texas, Marshall Division, against Par Pharmaceutical on April 23, 2014 seeking an injunction to prevent the approval of Par Pharmaceutical’s ANDA and/or to prevent Par Pharmaceutical from selling a generic version of RAVICTI, and the Company has taken over and is responsible for this patent litigation. On September 15, 2015, the Company received notice from Par Pharmaceutical that it had filed a Paragraph IV Patent Certification alleging that U.S. Patent No. 9,095,559 (the “’559 patent”) is invalid and/or will not be infringed by Par Pharmaceutical’s manufacture, use or sale of the medicine for which the ANDA was submitted. On April 29, 2015, Par Pharmaceutical filed Petitions for IPR of the ’215 patent and the ’012 patent. The PTAB issued decisions instituting such IPRs on November 4, 2015. On December 14, 2015, the District Court Judge Roy Payne issued a stay pending a final written decision from the PTAB with respect to the IPRs of the ’215 patent and the ’012 patent. The PTAB must issue a final written decision on the IPRs of the ’215 patent and the ’012 patent no later than November 4, 2016. On September 4, 2015, the Company received notice from Lupin of Lupin’s Paragraph IV Patent Certification against the ’215 patent and the ’012 patent, advising that Lupin had filed an ANDA with the FDA for a generic version of RAVICTI. On November 6, 2015, the Company also received Notice of Lupin’s Paragraph IV Patent Certification against the ’559 patent. Lupin has not advised the Company as to the timing or status of the FDA’s review of its filing. On October 19, 2015 the Company filed suit in the United States District Court for the District of New Jersey against Lupin seeking an injunction to prevent the approval of the ANDA. The lawsuit alleges that Lupin has infringed the ’215 patent, the ’012 patent and the ’559 patent by filing an ANDA seeking approval from the FDA to market generic versions of RAVICTI prior to the expiration of the patents. The subject patents are listed in the Orange Book. On April 6, 2016, the Company filed an Amended Complaint in the United States District Court for the District of New Jersey against Lupin alleging that Lupin has infringed the ’559 patent by filing an ANDA seeking approval from the FDA to market generic versions of RAVICTI prior to expiration of the ’559 patent. The commencement of the patent infringement lawsuit stays, or bars, FDA approval of Lupin’s ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or are invalid. The court has not yet set a trial date for the Lupin action. On April 1, 2016, Lupin filed a Petition to request an IPR of the ’559 patent. The PTAB will decide whether to institute an IPR on the ’559 patent no later than October 1, 2016. On August 3, 2015, HPI filed a lawsuit in the Superior Court of the State of California, County of Santa Clara, naming as defendants Depomed, Inc. (“Depomed”) and the members of its board of directors (the “Depomed Board”), Vicente J. Anido, Jr., Karen A. Dawes, Louis J. Lavigne, Jr., Samuel R. Saks, James A. Schoeneck, Peter D. Staple and David B. Zenoff. The lawsuit is captioned Horizon Pharma, Inc. v. Vicente J. Anido, Jr., et al., On August 3, 2015, Depomed filed a Complaint in the Superior Court of the State of California, County of Santa Clara, against the Company. The lawsuit is captioned Depomed, Inc. v. Horizon Pharma plc and Horizon Pharma, Inc., ® In November 2015, Express Scripts filed suit against the Com

Debt Agreements

Debt Agreements	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt Agreements	NOTE 14 – DEBT AGREEMENTS The Company’s outstanding debt balances as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 2015 Term Loan Facility $ 397,000 $ 398,000 2023 Senior Notes 475,000 475,000 Exchangeable Senior Notes due 2022 400,000 400,000 Total face value 1,272,000 1,273,000 Debt discount (123,885 ) (127,885 ) Deferred financing fees (7,935 ) (8,359 ) Total long-term debt 1,140,180 1,136,756 Less: current maturities 4,000 4,000 Long-term debt, net of current maturities $ 1,136,180 $ 1,132,756 The Company adopted ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . 2015 Senior Secured Credit Facility On May 7, 2015, HPI, the Company and certain of its subsidiaries entered into a credit agreement with Citibank, N.A., as administrative and collateral agent, and the lenders from time to time party thereto (the “credit agreement”) providing for (i) the six-year $400.0 million term loan facility (the The obligations under the credit agreement and any swap obligations and cash management obligations owing to a lender (or an affiliate of a lender) thereunder are and will be guaranteed by the Company and each of the Company’s existing and subsequently acquired or organized direct and indirect subsidiaries (other than certain immaterial subsidiaries, subsidiaries whose guarantee would result in material adverse tax consequences and subsidiaries whose guarantee is prohibited by applicable law). The obligations under the credit agreement and any such swap and cash management obligations are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (i) all tangible and intangible assets of the borrowers and the guarantors, except for certain customary excluded assets, and (ii) all of the capital stock owned by the borrowers and guarantors thereunder (limited, in the case of the stock of certain non-U.S. subsidiaries of the borrowers, to 65% of the capital stock of such subsidiaries). The borrowers are permitted to make voluntary prepayments at any time without payment of a premium. HPI is required to make mandatory prepayments of loans under the 2015 Term Loan Facility (without payment of a premium) with (a) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (b) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions), (c) net cash proceeds from issuances of debt (other than certain permitted debt), and (d) beginning with the fiscal year ending December 31, 2016, 50% of the Company’s excess cash flow (subject to decrease to 25% or 0% if the Company’s first lien leverage ratio is less than 2.25:1 and 1.75:1, respectively). The loans under the 2015 Term Loan Facility will amortize in equal quarterly installments in an aggregate annual amount equal to 1% of the original principal amount thereof, with any remaining balance payable on the final maturity date of the loans under the 2015 Term Loan Facility. The credit agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions, and customary events of default. As of March 31, 2016, the fair value of the 2015 Term Loan Facility was approximately $379.1 million, categorized as a Level 2 instrument, as defined in Note 11. 2023 Senior Notes On April 29, 2015, Horizon Financing, a wholly-owned subsidiary of the Company, completed a private placement of $475.0 million aggregate principal amount of the Senior Notes (the “2023 Senior Notes”), to certain investment banks acting as initial purchasers who subsequently resold the 2023 Senior Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and in offshore transactions to non-U.S. persons in reliance on Regulation S under the Securities Act. In connection with the closing of the Hyperion acquisition on May 7, 2015, Horizon Financing merged with and into HPI and, as a result, the 2023 Senior Notes became HPI’s general unsecured senior obligations and the Company and all of the Company’s direct and indirect subsidiaries that are guarantors under the 2015 Senior Secured Credit Facility fully and unconditionally guaranteed on a senior unsecured basis HPI’s obligations under the 2023 Senior Notes. The 2023 Senior Notes accrue interest at an annual rate of 6.625% payable semiannually in arrears on May 1 and November 1 of each year, beginning on November 1, 2015. The 2023 Senior Notes will mature on May 1, 2023, unless earlier exchanged, repurchased or redeemed. Except as described below, the 2023 Senior Notes may not be redeemed before May 1, 2018. Thereafter, some or all of the 2023 Senior Notes may be redeemed at any time at specified redemption prices, plus accrued and unpaid interest to the redemption date. At any time prior to May 1, 2018, some or all of the 2023 Senior Notes may be redeemed at a price equal to 100% of the aggregate principal amount thereof, plus a make-whole premium and accrued and unpaid interest to the redemption date. Also prior to May 1, 2018, up to 35% of the aggregate principal amount of the 2023 Senior Notes may be redeemed at a redemption price of 106.625% of the aggregate principal amount thereof, plus accrued and unpaid interest, with the net proceeds of certain equity offerings. In addition, the 2023 Senior Notes may be redeemed in whole but not in part at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest and additional amounts, if any, to, but excluding, the redemption date, if on the next date on which any amount would be payable in respect of the 2023 Senior Notes, HPI or any guarantor is or would be required to pay additional amounts as a result of certain tax-related events. If the Company undergoes a change of control, HPI will be required to make an offer to purchase all of the 2023 Senior Notes at a price in cash equal to 101% of the aggregate principal amount thereof plus accrued and unpaid interest to, but not including, the repurchase date. If the Company or certain of its subsidiaries engages in certain asset sales, HPI will be required under certain circumstances to make an offer to purchase the 2023 Senior Notes at 100% of the principal amount thereof, plus accrued and unpaid interest to the repurchase date. The indenture governing the 2023 Senior Notes contains covenants that limit the ability of the Company and its restricted subsidiaries to, among other things, pay dividends or distributions, repurchase equity, prepay junior debt and make certain investments, incur additional debt and issue certain preferred stock, incur liens on assets, engage in certain asset sales, merge, consolidate with or merge or sell all or substantially all of their assets, enter into transactions with affiliates, designate subsidiaries as unrestricted subsidiaries, and allow to exist certain restrictions on the ability of restricted subsidiaries to pay dividends or make other payments to the Company. Certain of the covenants will be suspended during any period in which the notes receive investment grade ratings. The indenture also includes customary events of default. As of March 31, 2016, the fair value of the 2023 Senior Notes was approximately $415.6 million, categorized as a Level 2 instrument, as defined in Note 11. Exchangeable Senior Notes On March 13, 2015, Horizon Investment completed a private placement of $400.0 million aggregate principal amount of Exchangeable Senior Notes to several investment banks acting as initial purchasers who subsequently resold the Exchangeable Senior Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act. The net proceeds from the offering of the Exchangeable Senior Notes were approximately $387.2 million, after deducting the initial purchasers’ discount and offering expenses payable by Horizon Investment. The Exchangeable Senior Notes are fully and unconditionally guaranteed, on a senior unsecured basis, by the Company (the “Guarantee”). The Exchangeable Senior Notes and the Guarantee are Horizon Investment’s and the Company’s senior unsecured obligations. The Exchangeable Senior Notes accrue interest at an annual rate of 2.50% payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2015. The Exchangeable Senior Notes will mature on March 15, 2022, unless earlier exchanged, repurchased or redeemed. The initial exchange rate is 34.8979 ordinary shares of the Company per $1,000 principal amount of the Exchangeable Senior Notes (equivalent to an initial exchange price of approximately $28.66 per ordinary share). The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon a tax redemption, Horizon Investment will increase the exchange rate for a holder who elects to exchange its Exchangeable Senior Notes in connection with such a corporate event or a tax redemption in certain circumstances. Other than as described below, the Exchangeable Senior Notes may not be redeemed by the Company. Issuer Redemptions: Optional Redemption for Changes in the Tax Laws of a Relevant Taxing Jurisdiction Horizon Investment may redeem the Exchangeable Senior Notes at its option, prior to March 15, 2022, in whole but not in part, in connection with certain tax-related events. Provisional Redemption on or After March 20, 2019 On or after March 20, 2019, Horizon Investment may redeem for cash all or a portion of the Exchangeable Senior Notes if the last reported sale price of ordinary shares of the Company has been at least 130% of the exchange price then in effect for at least 20 trading days whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Horizon Investment provide written notice of redemption. The redemption price will be equal to 100% of the principal amount of the Exchangeable Senior Notes to be redeemed, plus accrued and unpaid interest to, but not including, the redemption date; provided that if the redemption date occurs after a regular record date and on or prior to the corresponding interest payment date, Horizon Investment will pay the full amount of accrued and unpaid interest due on such interest payment date to the record holder of the Exchangeable Senior Notes on the regular record date corresponding to such interest payment date, and the redemption price payable to the holder who presents an Exchangeable Senior Note for redemption will be equal to 100% of the principal amount of such Exchangeable Senior Note. Holder Exchange Rights: Holders may exchange all or any portion of their Exchangeable Senior Notes at their option at any time prior to the close of business on the business day immediately preceding December 15, 2021 only upon satisfaction of one or more of the following conditions: 1. Exchange upon Satisfaction of Sale Price Condition 2. Exchange upon Satisfaction of Trading Price Condition 3. Exchange upon Notice of Redemption As of March 31, 2016, none of the above conditions had been satisfied and no exchange of Exchangeable Senior Notes had been triggered. On or after December 15, 2021, a holder may exchange all or any portion of its Exchangeable Senior Notes at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date regardless of the foregoing conditions. Upon exchange, Horizon Investment will settle exchanges of the Exchangeable Senior Notes by paying or causing to be delivered, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at its election. The Company recorded the Exchangeable Senior Notes under the guidance in Topic ASC 470-20, Debt with Conversion and Other Options, As of March 31, 2016, the fair value of the Exchangeable Senior Notes was approximately $340.8 million, categorized as a Level 2 instrument, as defined in Note 11. 2014 Senior Secured Credit Facility On June 17, 2014, the Company entered into a credit agreement with a group of lenders and Citibank, N.A., as administrative and collateral agent to provide the Company with $300.0 million in financing through a five-year senior secured credit facility (the “2014 Senior Secured Credit Facility”). Loans under the five-year $300.0 million term loan facility (“2014 Term Loan Facility”) bore interest, at each borrower’s option, at a rate equal to either the LIBOR, plus an applicable margin of 8.0% per year (subject to a 1.0% LIBOR floor), or the prime lending rate, plus an applicable margin equal to 7.0% per year. The Company borrowed the full $300.0 million available on the 2014 Term Loan Facility on September 19, 2014 as a LIBOR-based borrowing. On May 7, 2015, the Company repaid the entire $300.0 million outstanding amount under the 2014 Senior Secured Credit Facility in connection with the closing of the Hyperion acquisition and recognized a $56.8 million loss on debt extinguishment as a result of the early repayment. Convertible Senior Notes On November 22, 2013, the Company issued $150.0 million aggregate principal amount of 5.00% Convertible Senior Notes due 2018 (“Convertible Senior Notes”), and received net proceeds of $143.6 million, after deducting fees and expenses of $6.4 million. During 2015, the Company entered into separate, privately-negotiated conversion agreements with certain holders of the Convertible Senior Notes (“2015 Conversions”) which were on substantially the same terms as prior conversion agreements entered into by the Company. Under the 2015 Conversions, the applicable holders agreed to convert an aggregate principal amount of $61.0 million of Convertible Senior Notes held by them and the Company agreed to settle such conversions by issuing an aggregate of 11,368,921 ordinary shares. In addition, pursuant to such conversion agreements, the Company made an aggregate cash payment of $10.0 million to the applicable holders for additional exchange consideration and $0.9 million for accrued and unpaid interest, and recognized a non-cash charge of $10.1 million related to the extinguishment of debt as a result of the note conversions. Following the closings under the 2015 Conversions, there were no Convertible Senior Notes remaining outstanding.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Shareholders' Equity	NOTE 15 – SHAREHOLDERS’ EQUITY During the three months ended March 31, 2016, the Company issued an aggregate of 123,924 ordinary shares in connection with the exercise of stock options and received $0.9 million in proceeds. During the three months ended March 31, 2016, the Company issued an aggregate of 469,725 ordinary shares in net settlement of vested restricted stock units. During the three months ended March 31, 2016, the Company issued an aggregate of 13,584 ordinary shares in net settlement of vested performance stock units.

Share-Based Incentive Plans

Share-Based Incentive Plans	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Incentive Plans	NOTE 16 – SHARE-BASED INCENTIVE PLANS Employee Stock Purchase Plan 2014 Employee Stock Purchase Plan . On May 17, 2014, HPI’s board of directors adopted the 2014 Employee Stock Purchase Plan (the “2014 ESPP”). On September 18, 2014, at a special meeting of the stockholders of HPI (the “Special Meeting”), HPI’s stockholders approved the 2014 ESPP. Upon consummation of the Vidara Merger, the Company assumed the 2014 ESPP. As of March 31, 2016, an aggregate of 9,338,059 ordinary shares were authorized and available for future issuance under the 2014 ESPP. Refer to the Changes in Shares Authorized for Issuance under Share-Based Incentive Plans Share-Based Compensation Plans 2005 Stock Plan . In October 2005, HPI adopted the 2005 Stock Plan (the “2005 Plan”). Upon the signing of the underwriting agreement related to HPI’s initial public offering, on July 28, 2011, no further option grants were made under the 2005 Plan. All stock awards granted under the 2005 Plan prior to July 28, 2011 continue to be governed by the terms of the 2005 Plan. Upon consummation of the Vidara Merger, the Company assumed the 2005 Plan. 2011 Equity Incentive Plan . In July 2010, HPI’s board of directors adopted the 2011 Equity Incentive Plan (the “2011 EIP”). In June 2011, HPI’s stockholders approved the 2011 EIP, and it became effective upon the signing of the underwriting agreement related to HPI’s initial public offering on July 28, 2011. Upon consummation of the Vidara Merger, the Company assumed the 2011 EIP, and upon the effectiveness of the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan (the “2014 EIP”), no additional stock awards were or will be made under the 2011 Plan, although all outstanding stock awards granted under the 2011 Plan continue to be governed by the terms of the 2011 Plan. 2014 Equity Incentive Plan and 2014 Non-Employee Equity Plan . On May 17, 2014, HPI’s board of directors adopted the 2014 EIP and the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan (the “2014 Non-Employee Equity Plan”). At the Special Meeting, HPI’s stockholders approved the 2014 EIP and 2014 Non-Employee Equity Plan. Upon consummation of the Vidara Merger, the Company assumed the 2014 EIP and 2014 Non-Employee Equity Plan, which serve as successors to the 2011 EIP. The 2014 EIP provides for the grant of incentive and nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other stock awards that may be settled in cash, shares or other property to the employees of the Company (or a subsidiary company). The number of ordinary shares of the Company that were initially authorized for issuance under the 2014 EIP was no more than 22,052,130, which number consisted of (i) 15,500,000 ordinary shares of the Company; plus (ii) the number of shares available for issuance pursuant to the grant of future awards under the 2011 EIP; plus (iii) any shares subject to outstanding stock awards granted under the 2011 EIP and the 2005 Plan that expire or terminate for any reason prior to exercise or settlement or are forfeited, redeemed or repurchased because of the failure to meet a contingency or condition required to vest such shares; less (iv) 10,000,000 shares, which is the additional number of shares which were previously approved as an increase to the share reserve of the 2011 EIP. On March 23, 2015, the compensation committee of the Company’s board of directors approved amending the 2014 EIP subject to shareholder approval to, among other things, increase the aggregate number of shares authorized for issuance under the 2014 EIP by an additional 14,000,000 shares. On May 6, 2015, the shareholders of the Company approved such amendment to the 2014 EIP. The Company’s board of directors has authority to suspend or terminate the 2014 EIP at any time. The 2014 Non-Employee Equity Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other forms of stock awards that may be settled in cash, shares or other property to the non-employee directors and consultants of the Company (or a subsidiary company). The total number of ordinary shares of the Company that were initially authorized for issuance under the 2014 Non-Employee Equity Plan is 2,500,000. The Company’s board of directors has authority to suspend or terminate the 2014 Non-Employee Equity Plan at any time. As of March 31, 2016, an aggregate of 956,119 and 2,251,207 ordinary shares were authorized and available for future grants under the 2014 EIP and 2014 Non-Employee Equity Plan, respectively. Refer to the Changes in Shares Authorized for Issuance under Share-Based Incentive Plans Changes in Shares Authorized for Issuance under Share-Based Incentive Plans Further to the above, on February 25, 2016, the compensation committee of the Company’s board of directors approved, subject to shareholder approval, amending the 2014 EIP to, among other things, increase the aggregate number of shares authorized for issuance under the 2014 EIP beyond those remaining available for future grant under the 2014 EIP by an additional 6,000,000 shares and also approved a reduction in the number of shares authorized under our 2014 Non-Employee Equity Plan and 2014 ESPP by 1,000,000 shares and 5,000,000 shares, respectively, contingent on shareholder approval of the amendment to the 2014 EIP. On May 3, 2016, the shareholders of the Company approved the amendment to the 2014 EIP. Stock Options The following table summarizes stock option activity during the three months ended March 31, 2016: Options Weighted Average Exercise Price Weighted Average Contractual Term Remaining Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2015 13,385,791 $ 17.73 Granted 1,471,620 $ 18.55 Exercised (123,924 ) $ 7.86 Forfeited (536,920 ) $ 19.28 Expired (773 ) $ 12.68 Outstanding as of March 31, 2016 14,195,794 $ 17.84 8.26 $ 42,454 Exercisable as of March 31, 2016 4,931,406 $ 12.16 6.86 $ 30,270 Stock options typically have a contractual term of 10 years from grant date. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value of each stock option is affected by the Company’s share price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s expected share price volatility over the expected life of the awards and actual and projected stock option exercise behavior. The weighted average fair value per share of stock option awards granted during the three months ended March 31, 2016 and 2015, and assumptions used to value stock options, are as follows: For the Three Months Ended March 31, 2016 2015 Dividend yield — — Risk-free interest rate 1.3% - 1.8% 1.3% - 1.7% Weighted average volatility 74.0% 77.4% Expected life (in years) 6.1 6.0 Weighted average grant date fair value per share of options granted $ 12.12 $ 14.32 Dividend yield The Company has never paid dividends and does not anticipate paying any dividends in the near future. Additionally, the 2015 Senior Secured Credit Facility (described in Note 14 above) contains covenants that restrict the Company from issuing dividends. Risk-Free Interest Rate The Company determined the risk-free interest rate by using a weighted average assumption equivalent to the expected term based on the U.S. Treasury constant maturity rate as of the date of grant. Volatility The Company used an average historical share price volatility of comparable companies to be representative of future share price volatility, as the Company did not have sufficient trading history for its ordinary shares. Expected Term Given the Company’s limited historical exercise behavior, the expected term of options granted was determined using the “simplified” method since the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the expected term is presumed to be the average of the vesting term and the contractual life of the option. Forfeitures As share-based compensation expense recognized in the condensed consolidated statements of comprehensive loss is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures based on actual forfeiture experience, analysis of employee turnover and other factors. ASC Topic 718, Compensation-Stock Compensation Restricted Stock Units The following table summarizes restricted stock unit activity for the three months ended March 31, 2016: Number of Units Weighted Average Grant-Date Fair Value Per Units Outstanding as of December 31, 2015 3,361,746 $ 18.71 Granted 336,372 $ 17.75 Vested (697,500 ) $ 15.85 Forfeited (207,390 ) $ 19.57 Outstanding as of March 31, 2016 2,793,228 $ 19.24 The grant-date fair value of restricted stock units is the closing price of the Company’s shares on the date of grant. Performance Stock Unit Awards The following table summarizes performance stock unit awards (“PSUs”) activity for the three months ended March 31, 2016: Number of Units Weighted Average Grant-Date Fair Value Per Unit Average Illiquidity Discount Recorded Weighted Average Fair Value Per Unit Outstanding as of December 31, 2015 13,049,000 Granted 260,000 $ 7.99 8.2 % $ 7.34 Vested (20,000 ) $ 18.97 0.0 % $ 18.97 Forfeited (699,000 ) $ 14.39 17.1 % $ 11.93 Outstanding as of March 31, 2016 12,590,000 In January 2016, the compensation committee of the Company’s board of directors approved the grant of 260,000 PSUs to certain members of the Company’s senior leadership team. In 2014, the Company granted 25,000 PSUs. All other PSUs were granted in 2015 and 2016 and may vest if the Company’s total compounded annual shareholder rate of return (“TSR”) over three performance measurement periods summarized below equals or exceeds a minimum of 15%. Vesting Tranche Percent of Total PSU Award Beginning of Performance Measurement Period End of Performance Measurement Period Length of Performance Measurement Period (Years) Tranche One 33.3 % March 23, 2015 December 22, 2017 2.75 Tranche Two 33.3 % March 23, 2015 March 22, 2018 3.00 Tranche Three 33.3 % March 23, 2015 June 22, 2018 3.25 These PSUs granted in 2015 and 2016 will vest in amounts ranging from 25% to 100% based on the achievement of the following TSR over the three performance periods: TSR Achieved Vesting 15% 25 % 30% 50 % 45% 75 % 60% 100 % The TSR will be based on the volume weighted average trading price (“VWAP”) of the Company’s ordinary shares over the 20 trading days ending on the last day of each of the three performance measurement periods versus the VWAP of the Company’s ordinary shares over the 20 trading days ended March 23, 2015 of $21.50. These PSUs are subject to a post vesting holding period of one year for 50% of the PSUs and two years for 50% of the PSUs for executive committee members and one year for 50% of the PSUs for non-executive committee members. The Company accounts for the PSUs as equity-settled awards in accordance with ASC 718. Because the value of the PSUs granted in 2015 and 2016 is dependent upon the attainment of a level of TSR, it requires the impact of the market condition to be considered when estimating the fair value of the PSUs. As a result, the Monte Carlo model is applied and the most significant valuation assumptions used include: For the Three Months Ended March 31, 2016 2015 Valuation date stock price $ 17.72 - 21.07 $ 22.77 Expected volatility 76.8% - 77.6% 67.3 % Risk free rate 1.0% - 1.2% 1.0 % The average estimated fair value of each outstanding PSU granted under the 2014 EIP is as follows: Number of Units Weighted Average Fair Value Per Unit Average Illiquidity Discount Recorded Weighted Average Fair Value Per Unit Executive committee members 9,173,000 $ 15.18 18.3 % $ 12.40 Non-executive committee members 3,392,000 $ 13.60 7.3 % $ 12.60 12,565,000 $ 14.75 15.6 % $ 12.46 For the three months ended March 31, 2016, the Company recorded $12.7 million of expense related to PSUs. Cash Long-Term Incentive Program On November 5, 2014, the compensation committee of the Company’s board of directors approved a performance cash long-term incentive program for the members of the Company’s executive committee and executive leadership team, including its executive officers (the “Cash Bonus Program”). Participants in the Cash Bonus Program will be eligible for a specified cash bonus. The Cash Bonus Program pool funding of approximately $16.5 million was determined based on the Company’s actual TSR over the period from November 5, 2014 to May 6, 2015, and the bonus will be earned and payable only if the TSR for the period from November 5, 2014 to November 4, 2017 is greater than 15%. The portion of the total bonus pool payable to individual participants is based on allocations established by the Company’s compensation committee. Participants must remain employed by the Company through November 4, 2017 unless a participant’s earlier departure from employment is due to death, disability, termination without cause or a change in control transaction. Bonus payments under the Cash Bonus Program, if any, will be made after November 4, 2017. The Company accounts for the Cash Bonus Program under the liability method in accordance with ASC 718. Because vesting of the bonus pool is dependent upon the attainment of a VWAP of $18.37 or higher over the 20 trading days ending November 4, 2017, the Cash Bonus Program will be considered to be subject to a “market condition” for the purposes of ASC 718. ASC 718 requires the impact of the market condition to be considered when estimating the fair value of the bonus pool. As a result, the Monte Carlo simulation model is applied and the fair value is revalued at each reporting period. As of March 31, 2016 and December 31, 2015, the estimated fair value was $4.7 million and $6.0 million, respectively. For the three months ended March 31, 2016, the Company recorded $0.1 million of a release to the unaudited condensed consolidated statement of comprehensive loss as a result of the decrease in the valuation of the Cash Bonus Program. The most significant valuation assumptions used as of March 31, 2016 include: · Valuation Date Stock Price - $16.57. · Expected Volatility - The expected volatility assumption of 72.32% is based on the Company’s historical volatility over the 1.6 year period ending March 31, 2016, based upon daily stock price observations. · Risk Free Rate – 0.67%, which is based upon the yield on U.S. Treasury Separate Trading of Registered Interest and Principal Securities with a remaining term of 1.6 years as of March 31, 2016. Share-Based Compensation Expense The following table summarizes share-based compensation expense included in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 (in thousands): For the Three Months Ended March 31, 2016 2015 Share-based compensation expense: Research and development $ 2,125 $ 458 Sales and marketing 5,678 2,801 General and administrative 19,809 3,415 Total share-based compensation expense $ 27,612 $ 6,674 No material income tax benefit has been recognized relating to share-based compensation expense and no tax benefits have been realized from exercised stock options, due to the Company’s net loss position. As of March 31, 2016, the Company estimates that pre-tax unrecognized compensation expense of $276.9 million for all unvested share-based awards, including stock options, restricted stock units and PSUs, will be recognized through the first quarter of 2020. The Company expects to satisfy the exercise of stock options and future distribution of shares for restricted stock units and PSUs by issuing new ordinary shares which have been reserved under the 2014 EIP.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 17 – INCOME TAXES The Company accounts for income taxes based upon an asset and liability approach. Deferred tax assets and liabilities represent the future tax consequences of the differences between the financial statement carrying amounts of assets and liabilities versus the tax basis of assets and liabilities. Under this method, deferred tax assets are recognized for deductible temporary differences, and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences. Deferred tax assets are reduced by valuation allowances when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of tax rate changes on deferred tax assets and liabilities is recognized in the period in which the change is enacted. The following table presents the (benefit) expense for income taxes for the three months ended March 31, 2016 and 2015 (in thousands): For the Three Months Ended March 31, 2016 2015 Loss before (benefit) expense for income taxes $ (46,849 ) $ (17,640 ) (Benefit) expense for income taxes (1,443 ) 1,913 Net loss $ (45,406 ) $ (19,553 ) During the three months ended March 31, 2016, the Company recorded a benefit for income taxes of $1.4 million compared to an expense for income taxes of $1.9 million during the three months ended March 31, 2015. The income tax benefit during the three months ended March 31, 2016 was primarily attributable to losses incurred in higher tax rate jurisdictions during the period. The income tax expense during the three months ended March 31, 2015 was primarily attributable to the inability to recognize the benefit of losses in the United States due to valuation allowances as well as reserving for net operating losses utilized and minimum local jurisdictional tax liabilities realized. Deferred tax assets and liabilities arise from acquisition accounting adjustments where book values of certain assets and liabilities differ from their tax bases. Deferred tax assets and liabilities are recorded at the currently enacted rates which will be in effect at the time when the temporary differences are expected to reverse in the country where the underlying assets and liabilities are located. During the three months ended March 31, 2016, the Company acquired Crealta and its subsidiaries. The impact of the Crealta acquisition on the Company’s net deferred tax liability position was an increase to the net deferred tax liability of $20.8 million.

Basis of Presentation and Bus23

Basis of Presentation and Business Overview (Policies)	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair statement of the financial statements have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The December 31, 2015 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. On September 19, 2014, the businesses of Horizon Pharma, Inc. (“HPI”) and Vidara Therapeutics International Public Limited Company (“Vidara”) were combined in a merger transaction (the “Vidara Merger”), accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with HPI treated as the acquiring company in the Vidara Merger for accounting purposes. As part of the Vidara Merger, a wholly-owned subsidiary of Vidara merged with and into HPI, with HPI surviving the Vidara Merger as a wholly-owned subsidiary of Vidara. Prior to the Vidara Merger, Vidara changed its name to Horizon Pharma plc (the “Company”). Upon the consummation of the Vidara Merger, the historical financial statements of HPI became the Company’s historical financial statements. On May 7, 2015, the Company completed its acquisition of Hyperion Therapeutics Inc. (“Hyperion”) in which the Company acquired all of the issued and outstanding shares of Hyperion’s common stock for $46.00 per share in cash or approximately $1.1 billion on a fully-diluted basis. Following the completion of the acquisition, Hyperion became a wholly-owned subsidiary of the Company and was renamed as Horizon Therapeutics, Inc. On January 13, 2016 completed its acquisition of The unaudited condensed consolidated financial statements presented herein include the results of operations of the acquired businesses from the date of acquisition. See Note 3 for further details of business acquisitions. Unless otherwise indicated or the context otherwise requires, references to the “Company”, “we”, “us” and “our” refer to Horizon Pharma plc and its consolidated subsidiaries, including its predecessor, HPI. All references to “Vidara” are references to Horizon Pharma plc (formerly known as Vidara Therapeutics International Public Limited Company) and its consolidated subsidiaries prior to the effective time of the Vidara Merger on September 19, 2014. The unaudited condensed consolidated financial statements presented herein include the accounts of the Company and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated.
Revision of Prior Period Financial Statements	Revision of Prior Period Financial Statements In the course of preparing the Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2016, the Company determined that there had been an error in the presentation of the line titled “Foreign currency translation adjustments” for the previously reported three months ended March 31, 2015 (the “Affected Financial Statement”). The Affected Financial Statement presented foreign currency translation adjustment of $1,864,000 as a loss rather than income. Accounting Changes and Error Corrections, Assessing Materiality Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements For the Three Months Ended March 31, 2015 As reported As adjusted Net loss $ (19,553 ) $ (19,553 ) Foreign currency translation adjustments (1,864 ) $ 1,864 Other comprehensive (loss) income (1,864 ) 1,864 Comprehensive loss $ (21,417 ) $ (17,689 )
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, the Company adopts, as of the specified effective date, new accounting pronouncements issued by the FASB or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. As of December 31, 2015 As filed Reclassification As adjusted Other non-current assets $ 8,581 $ (8,359 ) $ 222 Exchangeable notes, net (283,675 ) 786 (282,889 ) Long-term debt, net, net of current (857,440 ) 7,573 (849,867 ) In April 2015, the FASB issued ASU No. 2015-05: Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB Issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Basis of Presentation and Bus24

Basis of Presentation and Business Overview (Tables)	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Effect of Revision on Condensed Consolidated Statement of Comprehensive Loss	The following are selected line items from the Company’s unaudited condensed consolidated statement of comprehensive loss illustrating the effect of the revision (in thousands): For the Three Months Ended March 31, 2015 As reported As adjusted Net loss $ (19,553 ) $ (19,553 ) Foreign currency translation adjustments (1,864 ) $ 1,864 Other comprehensive (loss) income (1,864 ) 1,864 Comprehensive loss $ (21,417 ) $ (17,689 )
Schedule of Adjustments Made to Conform Prior Period Classifications	The following table summarizes the adjustments made to conform prior period classifications as a result of the new guidance (in thousands): As of December 31, 2015 As filed Reclassification As adjusted Other non-current assets $ 8,581 $ (8,359 ) $ 222 Exchangeable notes, net (283,675 ) 786 (282,889 ) Long-term debt, net, net of current (857,440 ) 7,573 (849,867 )

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	The following table presents basic and diluted net loss per share for the three months ended March 31, 2016 and 2015 (in thousands, except share and per share data): For the Three Months Ended March 31, 2016 2015 Basic and diluted loss per share calculation: Net loss $ (45,406 ) $ (19,553 ) Weighted average ordinary shares outstanding 159,904,416 125,650,593 Basic and diluted net loss per share $ (0.28 ) $ (0.16 )

Business Acquisitions (Tables)

Business Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2016
Consolidated Pro Forma Financial Information	Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future (in thousands): For the Three Months Ended March 31, 2015 As reported Pro forma adjustments Pro forma Net sales $ 113,141 $ 40,613 $ 153,754 Net loss $ (19,553 ) $ (21,013 ) $ (40,566 )
Crealta Holdings LLC [Member]
Total Consideration for Acquisition	The total consideration for the acquisition was approximately $539.7 million, including cash acquired of $24.9 million, and was composed of the following (in thousands): Cash $ 536,181 Net settlements on the exercise of stock options and unrestricted units 3,526 Total consideration $ 539,707
Fair Values Assigned to Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary fair values assigned to the assets acquired and the liabilities assumed by the Company (in thousands): (Liabilities assumed) and assets acquired: Allocation Accounts payable and accrued expenses $ (4,543 ) Accrued trade discounts and rebates (1,424 ) Deferred tax liability (20,835 ) Other non-current liability (6,900 ) Contingent royalty liabilities (51,300 ) Cash and cash equivalents 24,893 Accounts receivable 10,014 Inventories 169,054 Prepaid expenses and other current assets 1,382 Developed technology 417,300 Other non-current assets 275 Goodwill 1,791 Fair value of consideration paid $ 539,707
Hyperion Therapeutics, Inc. [Member]
Total Consideration for Acquisition	The total consideration for the acquisition was approximately $1.1 billion and was composed of the following (in thousands, except share and per share data): Fully diluted equity value (21,425,909 shares at $46.00 per share) $ 985,592 Net settlements on the exercise of stock options, restricted stock and performance stock units 89,806 Total consideration $ 1,075,398
Fair Values Assigned to Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary fair values assigned to the assets acquired and the liabilities assumed by the Company (in thousands): (Liabilities assumed) and assets acquired: Allocation Deferred tax liability, net $ (262,732 ) Accounts payable (2,439 ) Accrued trade discounts and rebates (9,792 ) Accrued expenses (7,566 ) Contingent royalties (86,800 ) Cash and cash equivalents 53,037 Short-term investments 39,049 Long-term investments 25,574 Accounts receivable, net 11,858 Inventory 13,498 Prepaid expenses and other current assets 2,533 Property and equipment 1,044 Other non-current assets 123 Developed technology 1,044,200 Goodwill 253,811 Fair value of consideration paid $ 1,075,398

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Raw materials $ 1,719 $ 6,232 Work-in-process 143,245 631 Finished goods 35,238 11,513 Inventories, net $ 180,202 $ 18,376

Prepaid Expenses and Other Cu28

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Medicine samples inventory $ 5,154 $ 4,697 Prepaid co-pay expenses 1,949 1,881 Prepaid software license fees 1,217 1,638 Other prepaid expenses 9,162 7,642 Prepaid expenses and other current assets $ 17,482 $ 15,858

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	Property and equipment as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Machinery and equipment $ 2,834 $ 2,946 Computer equipment 2,797 2,514 Software 7,978 1,360 Leasehold improvements 6,788 1,966 Other 1,634 276 22,031 9,062 Less accumulated depreciation (4,693 ) (3,791 ) Construction in process 160 3,492 Software implementation in process 1,083 5,257 Property and equipment, net $ 18,581 $ 14,020

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Gross Carrying Amount of Goodwill	Goodwill The gross carrying amount of goodwill as of March 31, 2016 was as follows (in thousands): Balance at December 31, 2015 $ 253,811 Acquired during the period 1,791 Balance at March 31, 2016 $ 255,602
Amortizable Intangible Assets	As of March 31, 2016 and December 31, 2015, amortizable intangible assets consisted of the following (in thousands): March 31, 2016 December 31, 2015 Cost Accumulated Amortization Net Book Value Cost Basis Accumulated Amortization Net Book Value Developed technology $ 2,209,795 $ (232,893 ) $ 1,976,902 $ 1,792,495 $ (183,446 ) $ 1,609,049 Customer relationships 8,100 (1,242 ) 6,858 8,100 (1,039 ) 7,061 Total amortizable intangible assets $ 2,217,895 $ (234,135 ) $ 1,983,760 $ 1,800,595 $ (184,485 ) $ 1,616,110
Estimated Future Amortization Expense	As of March 31, 2016, estimated future amortization expense was as follows (in thousands): 2016 (April to December) $ 152,134 2017 202,946 2018 202,946 2019 189,953 2020 189,735 Thereafter 1,046,046 Total $ 1,983,760

Accrued Trade Discounts and R31

Accrued Trade Discounts and Rebates (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Schedule of Accrued Trade Discounts and Rebates	Accrued trade discounts and rebates as of , 2015 (in thousands): March 31, 2016 December 31, 2015 Accrued wholesaler fees and commercial rebates $ 24,482 $ 21,112 Accrued co-pay and other patient assistance 126,255 114,201 Accrued government rebates and chargebacks 73,633 48,456 Accrued trade discounts and rebates $ 224,370 $ 183,769 Invoiced wholesaler fees and commercial rebates, co-pay and other patient assistance, and government rebates and chargebacks in accounts payable 45,263 — Total customer-related accruals and allowances $ 269,633 $ 183,769
Schedule of Customer-Related Accruals and Allowances	The following table summarizes changes in the Company’s customer-related accruals and allowances from December 31, 2015 to March 31, 2016 (in thousands): Wholesaler Fees Co-Pay and Government and Commercial Other Patient Rebates and Rebates Assistance Chargebacks Total Balance at December 31, 2015 $ 21,112 $ 114,201 $ 48,456 $ 183,769 Current provisions relating to sales in the three months ended March 31, 2016 25,480 388,552 60,286 474,318 Adjustments relating to prior year sales 2,956 — (2,282 ) 674 Payments relating to sales in the three months ended March 31, 2016 (7,194 ) (224,243 ) (17,037 ) (248,474 ) Payments relating to sales in prior years (18,334 ) (114,189 ) (9,555 ) (142,078 ) Crealta acquisition on January 13, 2016 492 — 932 1,424 Balance at March 31, 2016 $ 24,512 $ 164,321 $ 80,800 $ 269,633

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2016
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 Payroll-related expenses $ 33,790 $ 47,205 Consulting and professional services 12,483 17,160 Accrued interest 16,187 10,637 Accrued other 26,680 25,044 Accrued expenses $ 89,140 $ 100,046

Accrued Royalties (Tables)

Accrued Royalties (Tables)	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Schedule of Changes in Liability for Royalties	Changes in the liability for royalties during the three months ended March 31, 2016 consisted of the following (in thousands): Balance as of December 31, 2015 $ 175,219 Assumed KRYSTEXXA and MIGERGOT accrued royalties 99 Assumed KRYSTEXXA and MIGERGOT contingent royalty liabilities 51,300 Royalty payments (8,944 ) Accretion expense 9,359 Balance as of March 31, 2016 227,033 Less: Current portion (54,588 ) Accrued royalties, net of current $ 172,445

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Assets and Liabilities at Fair Value on Recurring Basis	The following table sets forth the Company’s financial assets and liabilities at fair value on a recurring basis as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 Level 1 Level 2 Level 3 Total Assets: Bank time deposits $ — $ 1,500 $ — $ 1,500 Money market funds 210,280 — — 210,280 Total assets at fair value $ 210,280 $ 1,500 $ — $ 211,780 December 31, 2015 Level 1 Level 2 Level 3 Total Assets: Bank time deposits $ — $ 1,000 $ — $ 1,000 Money market funds 280,053 — — 280,053 Total assets at fair value $ 280,053 $ 1,000 $ — $ 281,053

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Schedule of Lease Agreements in Place for Real Properties	The Company has the following lease agreements in place for real properties: Location Approximate Square Footage Lease Expiry Date Dublin, Ireland 18,900 November 4, 2029 Lake Forest, Illinois (1) 160,000 March 31, 2024 Deerfield, Illinois (2) 53,500 June 30, 2018 Brisbane, California (3) 20,100 November 30, 2019 Mannheim, Germany 9,500 December 31, 2016 Chicago, Illinois 6,500 December 31, 2018 Roswell, Georgia 6,200 October 31, 2018 Reinach, Switzerland 3,500 May 31, 2020 (1) In connection with the Lake Forest, Illinois lease, the Company has provided a $2.0 million letter of credit to the landlord, through a commercial bank. The Company has two separate lease agreements in place for this property, one of which, consisting of approximately 15,000 square feet, was assumed by the Company as a result of its acquisition of Crealta in January 2016 and will expire on October 31, 2017. (2) The Company vacated the premises in Deerfield, Illinois in January 2016. (3) The Company vacated the premises in Brisbane, California in December 2015 and entered into a sublease agreement for the property with a third party.

Debt Agreements (Tables)

Debt Agreements (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Outstanding Debt Balances	The Company’s outstanding debt balances as of March 31, 2016 and December 31, 2015 consisted of the following (in thousands): March 31, 2016 December 31, 2015 2015 Term Loan Facility $ 397,000 $ 398,000 2023 Senior Notes 475,000 475,000 Exchangeable Senior Notes due 2022 400,000 400,000 Total face value 1,272,000 1,273,000 Debt discount (123,885 ) (127,885 ) Deferred financing fees (7,935 ) (8,359 ) Total long-term debt 1,140,180 1,136,756 Less: current maturities 4,000 4,000 Long-term debt, net of current maturities $ 1,136,180 $ 1,132,756

Share-Based Incentive Plans (Ta

Share-Based Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of Stock Option Activity	The following table summarizes stock option activity during the three months ended March 31, 2016: Options Weighted Average Exercise Price Weighted Average Contractual Term Remaining Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2015 13,385,791 $ 17.73 Granted 1,471,620 $ 18.55 Exercised (123,924 ) $ 7.86 Forfeited (536,920 ) $ 19.28 Expired (773 ) $ 12.68 Outstanding as of March 31, 2016 14,195,794 $ 17.84 8.26 $ 42,454 Exercisable as of March 31, 2016 4,931,406 $ 12.16 6.86 $ 30,270
Weighted Average Fair Value per Share of Stock Option Awards Granted and Assumptions Used to Value Stock Options	The weighted average fair value per share of stock option awards granted during the three months ended March 31, 2016 and 2015, and assumptions used to value stock options, are as follows: For the Three Months Ended March 31, 2016 2015 Dividend yield — — Risk-free interest rate 1.3% - 1.8% 1.3% - 1.7% Weighted average volatility 74.0% 77.4% Expected life (in years) 6.1 6.0 Weighted average grant date fair value per share of options granted $ 12.12 $ 14.32
Summary of Restricted Stock Unit Activity	The following table summarizes restricted stock unit activity for the three months ended March 31, 2016: Number of Units Weighted Average Grant-Date Fair Value Per Units Outstanding as of December 31, 2015 3,361,746 $ 18.71 Granted 336,372 $ 17.75 Vested (697,500 ) $ 15.85 Forfeited (207,390 ) $ 19.57 Outstanding as of March 31, 2016 2,793,228 $ 19.24
Summary of Performance Stock Unit Awards (PSUs) Activity	The following table summarizes performance stock unit awards (“PSUs”) activity for the three months ended March 31, 2016: Number of Units Weighted Average Grant-Date Fair Value Per Unit Average Illiquidity Discount Recorded Weighted Average Fair Value Per Unit Outstanding as of December 31, 2015 13,049,000 Granted 260,000 $ 7.99 8.2 % $ 7.34 Vested (20,000 ) $ 18.97 0.0 % $ 18.97 Forfeited (699,000 ) $ 14.39 17.1 % $ 11.93 Outstanding as of March 31, 2016 12,590,000
Summary of Vesting Tranches	In 2014, the Company granted 25,000 PSUs. All other PSUs were granted in 2015 and 2016 and may vest if the Company’s total compounded annual shareholder rate of return (“TSR”) over three performance measurement periods summarized below equals or exceeds a minimum of 15%. Vesting Tranche Percent of Total PSU Award Beginning of Performance Measurement Period End of Performance Measurement Period Length of Performance Measurement Period (Years) Tranche One 33.3 % March 23, 2015 December 22, 2017 2.75 Tranche Two 33.3 % March 23, 2015 March 22, 2018 3.00 Tranche Three 33.3 % March 23, 2015 June 22, 2018 3.25 These PSUs granted in 2015 and 2016 will vest in amounts ranging from 25% to 100% based on the achievement of the following TSR over the three performance periods: TSR Achieved Vesting 15% 25 % 30% 50 % 45% 75 % 60% 100 %
Summary of Average Estimated Fair Value of PSU	The average estimated fair value of each outstanding PSU granted under the 2014 EIP is as follows: Number of Units Weighted Average Fair Value Per Unit Average Illiquidity Discount Recorded Weighted Average Fair Value Per Unit Executive committee members 9,173,000 $ 15.18 18.3 % $ 12.40 Non-executive committee members 3,392,000 $ 13.60 7.3 % $ 12.60 12,565,000 $ 14.75 15.6 % $ 12.46
Summary of Share-Based Compensation Expense	The following table summarizes share-based compensation expense included in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 (in thousands): For the Three Months Ended March 31, 2016 2015 Share-based compensation expense: Research and development $ 2,125 $ 458 Sales and marketing 5,678 2,801 General and administrative 19,809 3,415 Total share-based compensation expense $ 27,612 $ 6,674
Performance Stock Units [Member]
Weighted Average Fair Value per Share of Stock Option Awards Granted and Assumptions Used to Value Stock Options	The Company accounts for the PSUs as equity-settled awards in accordance with ASC 718. Because the value of the PSUs granted in 2015 and 2016 is dependent upon the attainment of a level of TSR, it requires the impact of the market condition to be considered when estimating the fair value of the PSUs. As a result, the Monte Carlo model is applied and the most significant valuation assumptions used include: For the Three Months Ended March 31, 2016 2015 Valuation date stock price $ 17.72 - 21.07 $ 22.77 Expected volatility 76.8% - 77.6% 67.3 % Risk free rate 1.0% - 1.2% 1.0 %

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
(Benefit) Expense for Income Taxes	The following table presents the (benefit) expense for income taxes for the three months ended March 31, 2016 and 2015 (in thousands): For the Three Months Ended March 31, 2016 2015 Loss before (benefit) expense for income taxes $ (46,849 ) $ (17,640 ) (Benefit) expense for income taxes (1,443 ) 1,913 Net loss $ (45,406 ) $ (19,553 )

Basis of Presentation and Bus39

Basis of Presentation and Business Overview - Additional Information (Detail) - USD ($)	Jan. 13, 2016	May. 07, 2015	Mar. 31, 2016	Mar. 31, 2015
Basis Of Presentation [Line Items]
Foreign currency translation adjustments			$ (247,000)	$ 1,864,000
Percentage of patients filled prescriptions through prescriptions made easy program			96.00%
Aggregate commercial value of patient access programs			$ 388,600,000
Maximum [Member]
Basis Of Presentation [Line Items]
Patients with co-pay amounts under filling prescriptions through prescriptions made easy program			$ 10
As Reported [Member]
Basis Of Presentation [Line Items]
Foreign currency translation adjustments				$ (1,864,000)
Hyperion Therapeutics, Inc. [Member]
Basis Of Presentation [Line Items]
Business acquisition date			May 7, 2015
Common stock, price per share		$ 46
Consideration transferred		$ 1,075,398,000
Crealta Holdings LLC [Member]
Basis Of Presentation [Line Items]
Business acquisition date			Jan. 13, 2016
Consideration transferred	$ 539,707,000
Cash acquired from acquisition	$ 24,900,000

Basis of Presentation and Bus40

Basis of Presentation and Business Overview - Effect of Revision on Condensed Consolidated Statement of Comprehensive Loss (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Basis Of Presentation [Line Items]
Net loss	$ (45,406,000)	$ (19,553,000)
Foreign currency translation adjustments	(247,000)	1,864,000
Other comprehensive (loss) income	(247,000)	1,864,000
Comprehensive loss	$ (45,653,000)	(17,689,000)
As Reported [Member]
Basis Of Presentation [Line Items]
Net loss		(19,553,000)
Foreign currency translation adjustments		(1,864,000)
Other comprehensive (loss) income		(1,864,000)
Comprehensive loss		(21,417,000)
As Adjusted [Member]
Basis Of Presentation [Line Items]
Net loss		(19,553,000)
Foreign currency translation adjustments		1,864,000
Other comprehensive (loss) income		1,864,000
Comprehensive loss		$ (17,689,000)

Basis of Presentation and Bus41

Basis of Presentation and Business Overview - Schedule of Adjustments Made to Conform Prior Period Classifications (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Basis Of Presentation [Line Items]
Other non-current assets	$ 600	$ 222
Exchangeable notes, net	286,558	282,889
Long-term debt, net, net of current	$ 849,622	849,867
ASU 2015-03 [Member]
Basis Of Presentation [Line Items]
Other non-current assets		222
Exchangeable notes, net		(282,889)
Long-term debt, net, net of current		(849,867)
ASU 2015-03 [Member] | As Filed [Member]
Basis Of Presentation [Line Items]
Other non-current assets		8,581
Exchangeable notes, net		(283,675)
Long-term debt, net, net of current		(857,440)
ASU 2015-03 [Member] | Reclassification [Member]
Basis Of Presentation [Line Items]
Other non-current assets		(8,359)
Exchangeable notes, net		786
Long-term debt, net, net of current		$ 7,573

Net Loss per Share - Basic and

Net Loss per Share - Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Basic and diluted loss per share calculation:
Net loss	$ (45,406)	$ (19,553)
Weighted average ordinary shares outstanding	159,904,416	125,650,593
Basic and diluted net loss per share	$ (0.28)	$ (0.16)

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Mar. 13, 2015
Earnings Per Share [Line Items]
Senior notes	$ 400,000		$ 400,000
Incremental common shares attributable to dilutive effect of conversion of Exchangeable Senior Notes	0	0
Exchangeable Senior Notes [Member]
Earnings Per Share [Line Items]
Maturity year of debt instrument	2,022
Interest rate	2.50%
Horizon Investment [Member] | Exchangeable Senior Notes [Member]
Earnings Per Share [Line Items]
Senior notes				$ 400,000
Maturity year of debt instrument	2,022
Interest rate	2.50%

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jan. 13, 2016	May. 07, 2015	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015
Business Acquisition [Line Items]
Percentage of estimated cash flows expected to be realized			90.00%
Net sales			$ 204,690		$ 113,141
KRYSTEXXA Developed Technology [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets estimated useful life			12 years
MIGERGOT Developed Technology [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets estimated useful life			10 years
RAVICTI Developed Technology [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets estimated useful life			11 years
BUPHENYL Developed Technology [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets estimated useful life			7 years
Crealta Holdings LLC [Member]
Business Acquisition [Line Items]
Total consideration	$ 539,707
Cash acquired from acquisition	24,900
Acquisition related costs			$ 10,100
Inventory	169,054
Initial fair value of liability			51,300
Cash consideration	$ 536,181
Crealta Holdings LLC [Member] | Commercial Supply Agreements [Member]
Business Acquisition [Line Items]
Contingent liability			6,900
Crealta Holdings LLC [Member] | Fair Value Adjustment to Inventory [Member]
Business Acquisition [Line Items]
Inventory			163,600
Crealta Holdings LLC [Member] | KRYSTEXXA and MIGERGOT [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Amortization of inventory step up			7,400
Crealta Holdings LLC [Member] | KRYSTEXXA Developed Technology [Member]
Business Acquisition [Line Items]
Net sales			$ 16,200
Crealta Holdings LLC [Member] | KRYSTEXXA Developed Technology [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Present value at discount rate			27.00%
Crealta Holdings LLC [Member] | MIGERGOT Developed Technology [Member]
Business Acquisition [Line Items]
Net sales			$ 900
Crealta Holdings LLC [Member] | MIGERGOT Developed Technology [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Present value at discount rate			23.00%
Crealta Holdings LLC [Member] | General and Administrative [Member]
Business Acquisition [Line Items]
Acquisition related costs			$ 10,000
Crealta Holdings LLC [Member] | Cost of Goods Sold [Member]
Business Acquisition [Line Items]
Acquisition related costs			100
Hyperion Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Total consideration		$ 1,075,398
Acquisition related costs			700		$ 1,900
Inventory		$ 13,498
Initial fair value of liability			$ 86,800
Business acquisition share price		$ 46
Cash consideration		$ 1,100,000
Income tax rate reconciliation, tax settlement, domestic percent			39.00%
Business acquisition, valuation allowance recognized				$ 105,100
Hyperion Therapeutics, Inc. [Member] | Fair Value Adjustment to Inventory [Member]
Business Acquisition [Line Items]
Inventory			$ 8,700
Hyperion Therapeutics, Inc. [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Present value at discount rate			8.50%
Hyperion Therapeutics, Inc. [Member] | RAVICTI Developed Technology [Member]
Business Acquisition [Line Items]
Net sales			$ 37,100
Hyperion Therapeutics, Inc. [Member] | BUPHENYL Developed Technology [Member]
Business Acquisition [Line Items]
Net sales			$ 3,700

Business Acquisitions - Total C

Business Acquisitions - Total Consideration for Acquisition Including Cash Acquired (Detail) - Crealta Holdings LLC [Member] $ in Thousands	Jan. 13, 2016USD ($)
Business Acquisition [Line Items]
Cash	$ 536,181
Net settlements on the exercise of stock options and unrestricted units	3,526
Total consideration	$ 539,707

Business Acquisitions - Fair Va

Business Acquisitions - Fair Values Assigned to Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jan. 13, 2016	May. 07, 2015	Mar. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill			$ 255,602	$ 253,811
Crealta Holdings LLC [Member]
Business Acquisition [Line Items]
Accounts payable and accrued expenses	$ (4,543)
Accrued trade discounts and rebates	(1,424)
Deferred tax liability	(20,835)
Other non-current liability	(6,900)
Contingent royalties	(51,300)
Cash and cash equivalents	24,893
Accounts receivable, net	10,014
Inventories	169,054
Prepaid expenses and other current assets	1,382
Other non-current assets	275
Goodwill	1,791
Fair value of consideration paid	539,707
Crealta Holdings LLC [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 417,300
Hyperion Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Deferred tax liability, net		$ (262,732)
Accrued trade discounts and rebates		(9,792)
Accounts payable		(2,439)
Accrued expenses and other current liabilities		(7,566)
Contingent royalties		(86,800)
Cash and cash equivalents		53,037
Short-term investments		39,049
Long-term investments		25,574
Accounts receivable, net		11,858
Inventories		13,498
Prepaid expenses and other current assets		2,533
Property and equipment		1,044
Other non-current assets		123
Goodwill		253,811
Fair value of consideration paid		1,075,398
Hyperion Therapeutics, Inc. [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets		$ 1,044,200

Business Acquisitions - Total47

Business Acquisitions - Total Consideration for Acquisition (Detail) - Hyperion Therapeutics, Inc. [Member] $ in Thousands	May. 07, 2015USD ($)
Business Acquisition [Line Items]
Fully diluted equity value (21,425,909 shares at $46.00 per share)	$ 985,592
Net settlements on the exercise of stock options, restricted stock and performance stock units	89,806
Total consideration	$ 1,075,398

Business Acquisitions - Total48

Business Acquisitions - Total Consideration for Acquisition (Parenthetical) (Detail) - Hyperion Therapeutics, Inc. [Member]	May. 07, 2015$ / sharesshares
Business Acquisition [Line Items]
Fully diluted equity shares | shares	21,425,909
Price per share | $ / shares	$ 46

Business Acquisitions - Consoli

Business Acquisitions - Consolidated Pro Forma Financial Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2015USD ($)
Business Acquisition [Line Items]
Net sales	$ 153,754
Net loss	(40,566)
As Reported [Member]
Business Acquisition [Line Items]
Net sales	113,141
Net loss	(19,553)
As Adjusted [Member]
Business Acquisition [Line Items]
Net sales	40,613
Net loss	$ (21,013)

Inventories - Components of Inv

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 1,719	$ 6,232
Work-in-process	143,245	631
Finished goods	35,238	11,513
Inventories, net	$ 180,202	$ 18,376

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Work-in-process	$ 143,245	$ 631
Finished goods	35,238	$ 11,513
Crealta Holdings LLC [Member] | KRYSTEXXA Developed Technology [Member] | Developed Technology [Member]
Inventory [Line Items]
Work-in-process	135,500
Crealta Holdings LLC [Member] | MIGERGOT Developed Technology [Member] | Developed Technology [Member]
Inventory [Line Items]
Finished goods	20,700
Crealta Holdings LLC [Member] | KRYSTEXXA and MIGERGOT [Member] | Developed Technology [Member]
Inventory [Line Items]
Amortization of inventory step up	$ 7,400

Prepaid Expenses and Other Cu52

Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Medicine sample inventory	$ 5,154	$ 4,697
Prepaid co-pay expenses	1,949	1,881
Prepaid software license fees	1,217	1,638
Other prepaid expenses	9,162	7,642
Prepaid expenses and other current assets	$ 17,482	$ 15,858

Property and Equipment - Proper

Property and Equipment - Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 22,031	$ 9,062
Less accumulated depreciation	(4,693)	(3,791)
Property and equipment, net	18,581	14,020
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,834	2,946
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,797	2,514
Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,978	1,360
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	6,788	1,966
Other [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,634	276
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net	160	3,492
Software implementation in process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 1,083	$ 5,257

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 1	$ 0.7

Goodwill and Intangible Asset55

Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 253,811
Acquired during the period	1,791
Ending balance	$ 255,602

Goodwill and Intangible Asset56

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Jan. 31, 2016	May. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Jan. 13, 2016	Dec. 31, 2015	May. 07, 2015
Finite-Lived Intangible Assets [Line Items]
Goodwill			$ 255,602,000			$ 253,811,000
Amortization expense of developed technology			49,700,000	$ 17,700,000
Developed Technology [Member] | RAVICTI Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized intangible asset		$ 1,021,600,000
Developed Technology [Member] | BUPHENYL Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized intangible asset		22,600,000
Developed Technology [Member] | KRYSTEXXA Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized intangible asset	$ 392,700,000
Developed Technology [Member] | MIGERGOT Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized intangible asset	24,600,000
Hyperion Therapeutics, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill							$ 253,811,000
Hyperion Therapeutics, Inc. [Member] | As Filed [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 253,800,000
Crealta Holdings LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill					$ 1,791,000
Accumulated goodwill impairment losses			$ 0
Crealta Holdings LLC [Member] | As Filed [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 1,800,000

Goodwill and Intangible Asset57

Goodwill and Intangible Assets - Amortizable Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Cost Basis	$ 2,217,895	$ 1,800,595
Accumulated Amortization	(234,135)	(184,485)
Net Book Value	1,983,760	1,616,110
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Cost Basis	2,209,795	1,792,495
Accumulated Amortization	(232,893)	(183,446)
Net Book Value	1,976,902	1,609,049
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost Basis	8,100	8,100
Accumulated Amortization	(1,242)	(1,039)
Net Book Value	$ 6,858	$ 7,061

Goodwill and Intangible Asset58

Goodwill and Intangible Assets - Estimated Future Amortization Expense (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
2016 (April to December)	$ 152,134
2,017	202,946
2,018	202,946
2,019	189,953
2,020	189,735
Thereafter	1,046,046
Net Book Value	$ 1,983,760	$ 1,616,110

Accrued Trade Discounts and R59

Accrued Trade Discounts and Rebates - Schedule of Accrued Trade Discounts and Rebates (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Accrued wholesaler fees and commercial rebates	$ 24,482	$ 21,112
Accrued co-pay and other patient assistance	126,255	114,201
Accrued government rebates and chargebacks	73,633	48,456
Accrued trade discounts and rebates	224,370	183,769
Invoiced wholesaler fees and commercial rebates, co-pay and other patient assistance, and government rebates and chargebacks in accounts payable	45,263
Total customer-related accruals and allowances	$ 269,633	$ 183,769

Accrued Trade Discounts and R60

Accrued Trade Discounts and Rebates - Schedule of Customer-Related Accruals and Allowances (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning Balance	$ 183,769
Current provisions relating to sales	474,318
Adjustments relating to prior year sales	674
Payments relating to sales	(248,474)
Payments relating to sales in prior years	(142,078)
Ending Balance	269,633
Wholesaler Fees and Commercial Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning Balance	21,112
Current provisions relating to sales	25,480
Adjustments relating to prior year sales	2,956
Payments relating to sales	(7,194)
Payments relating to sales in prior years	(18,334)
Ending Balance	24,512
Co-Pay and Other Patient Assistance [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning Balance	114,201
Current provisions relating to sales	388,552
Payments relating to sales	(224,243)
Payments relating to sales in prior years	(114,189)
Ending Balance	164,321
Government Rebates and Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning Balance	48,456
Current provisions relating to sales	60,286
Adjustments relating to prior year sales	(2,282)
Payments relating to sales	(17,037)
Payments relating to sales in prior years	(9,555)
Ending Balance	80,800
Crealta Acquisition [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Merger and Acquisition	1,424
Crealta Acquisition [Member] | Wholesaler Fees and Commercial Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Merger and Acquisition	492
Crealta Acquisition [Member] | Government Rebates and Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Merger and Acquisition	$ 932

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Payroll-related expenses	$ 33,790	$ 47,205
Consulting and professional services	12,483	17,160
Accrued interest	16,187	10,637
Accrued other	26,680	25,044
Accrued expenses	$ 89,140	$ 100,046

Accrued Expenses - Additional I

Accrued Expenses - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule Of Accrued Expenses [Line Items]
Accrued payroll-related expenses	$ 33,790	$ 47,205
Hyperion Therapeutics, Inc. [Member] | Severance and related employee costs [Member]
Schedule Of Accrued Expenses [Line Items]
Accrued payroll-related expenses	5,400
Crealta Holdings LLC [Member] | Severance and related employee costs [Member]
Schedule Of Accrued Expenses [Line Items]
Accrued payroll-related expenses	$ 3,200

Accrued Royalties - Schedule of

Accrued Royalties - Schedule of Changes in Liability for Royalties (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Business Combinations [Abstract]
Beginning balance	$ 175,219
Assumed KRYSTEXXA and MIGERGOT accrued royalties	99
Assumed KRYSTEXXA and MIGERGOT contingent royalty liabilities	51,300
Royalty payments	(8,944)
Accretion expense	9,359	$ 3,044
Ending balance	227,033
Less: Current portion	(54,588)		$ (51,700)
Accrued royalties, net of current	$ 172,445		$ 123,519

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Transfers from level 1 to level 2, assets	$ 0	$ 0
Transfers from level 2 to level 1, assets	0	0
Transfers of assets into level 3	0	0
Transfers of assets out of level 3	$ 0	$ 0

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Detail) - Fair Value Measurements, Recurring Basis [Member] - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	$ 211,780	$ 281,053
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	210,280	280,053
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	1,500	1,000
Bank Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	1,500	1,000
Bank Time Deposits [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	1,500	1,000
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	210,280	280,053
Money Market Funds [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	$ 210,280	$ 280,053

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Lease Agreements in Place for Real Properties (Detail)	3 Months Ended
	Mar. 31, 2016ft²
Dublin Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	18,900
Lease Expiry Date	Nov. 4, 2029
Lake Forest Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	160,000	[1]
Lease Expiry Date	Mar. 31, 2024	[1]
Deerfield Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	53,500	[2]
Lease Expiry Date	Jun. 30, 2018	[2]
Brisbane Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	20,100	[3]
Lease Expiry Date	Nov. 30, 2019	[3]
Mannheim Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	9,500
Lease Expiry Date	Dec. 31, 2016
Chicago Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	6,500
Lease Expiry Date	Dec. 31, 2018
Roswell Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	6,200
Lease Expiry Date	Oct. 31, 2018
Reinach Office [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	3,500
Lease Expiry Date	May 31, 2020
[1]	In connection with the Lake Forest, Illinois lease, the Company has provided a $2.0 million letter of credit to the landlord, through a commercial bank. The Company has two separate lease agreements in place for this property, one of which, consisting of approximately 15,000 square feet, was assumed by the Company as a result of its acquisition of Crealta in January 2016 and will expire on October 31, 2017.
[2]	The Company vacated the premises in Deerfield, Illinois in January 2016.
[3]	The Company vacated the premises in Brisbane, California in December 2015 and entered into a sublease agreement for the property with a third party.

Commitments and Contingencies67

Commitments and Contingencies - Schedule of Lease Agreements in Place for Real Properties (Parenthetical) (Detail) - Lake Forest Office [Member] $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)ft²Agreement
Loss Contingencies [Line Items]
Letter of credit | $	$ 2
Approximate Square Footage	160,000	[1]
Lease Expiry Date	Mar. 31, 2024	[1]
Number Of Lease Agreements | Agreement	2
First Lease [Member]
Loss Contingencies [Line Items]
Approximate Square Footage	15,000
Lease Expiry Date	Oct. 31, 2017
[1]	In connection with the Lake Forest, Illinois lease, the Company has provided a $2.0 million letter of credit to the landlord, through a commercial bank. The Company has two separate lease agreements in place for this property, one of which, consisting of approximately 15,000 square feet, was assumed by the Company as a result of its acquisition of Crealta in January 2016 and will expire on October 31, 2017.

Commitments and Contingencies68

Commitments and Contingencies - Additional Information (Detail) $ in Millions	1 Months Ended	3 Months Ended
	Nov. 30, 2015USD ($)	Mar. 31, 2016USD ($)€ / $	Mar. 31, 2015USD ($)
Loss Contingencies [Line Items]
Minimum annual royalty obligations		$ 7.5
Alleged Unpaid Rebates and Administrative Fees [Member]
Loss Contingencies [Line Items]
Loss contingency, damages sought, value	$ 139.9
Cost of Goods Sold [Member]
Loss Contingencies [Line Items]
Royalty and royalty accretion expense recognized in cost of goods sold		$ 10.5	$ 3.6
Crealta Holdings LLC [Member] | Commercial Supply Agreements [Member]
Loss Contingencies [Line Items]
Manufacturing and supply agreement initiation date		2007-03
Binding purchase commitment		$ 2.5
Purchase obligation percentage		80.00%
Contingent liability		$ 6.9
Jagotec AG [Member]
Loss Contingencies [Line Items]
Term of commitment made by the company to purchase tablets		5 years
Written notice period for termination of agreement		2 years
Manufacturing and supply agreement initiation date		2007-08
Purchase commitment expiration date		Apr. 15, 2019
Sanofi-Aventis U.S [Member]
Loss Contingencies [Line Items]
Manufacturing and supply agreement initiation date		2011-05
Boehringer Ingelheim [Member]
Loss Contingencies [Line Items]
Manufacturing and supply agreement initiation date		2013-07
Binding purchase commitment		$ 15.9
Currency exchange rate | € / $		1.1381
Patheon [Member]
Loss Contingencies [Line Items]
Manufacturing and supply agreement initiation date		2013-11
Binding purchase commitment		$ 3.7
Aralez Pharmaceuticals Inc. [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales		10.00%
Royalty expiration period upon first commercial sale in united states		10 years
Genentech Inc [Member]
Loss Contingencies [Line Items]
Net sales threshold		$ 3.7
Genentech Inc [Member] | November 25, 2014 [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales		45.00%
Additional percentage of royalty on net sales		10.00%
Genentech Inc [Member] | November 26, 2014 through May 5, 2018 [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales		20.00%
Additional percentage of royalty on net sales		1.00%
Genentech Inc [Member] | November 26, 2014 through May 5, 2018 [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales		30.00%
Additional percentage of royalty on net sales		9.00%
Connetics Corporation [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales		0.25%
Net sales threshold		$ 1,000
Additional percentage of royalty on net sales		0.50%
Percentage of royalty on net sales upon regulatory approval		4.00%
LODOTRA and RAYOS Developed Technology [Member]
Loss Contingencies [Line Items]
Purchase commitment based on tablet and its pricing		$ 2.6
DUEXIS [Member]
Loss Contingencies [Line Items]
Purchase commitment based on tablet and its pricing		$ 8.9
PENNSAID 2% [Member]
Loss Contingencies [Line Items]
Manufacturing and supply agreement initiation date		2014-10
Binding purchase commitment		$ 9.1
Supply agreement expiry date		Dec. 31, 2029
Ravicti and Buphenyl [Member]
Loss Contingencies [Line Items]
Purchase commitment outstanding purchase orders		$ 5
RAVICTI [Member] | Lyne Laboratories Inc. [Member]
Loss Contingencies [Line Items]
Minimum purchase amount for next twelve months		$ 0.5

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Nov. 30, 2015	Mar. 31, 2016
Alleged Unpaid Rebates and Administrative Fees [Member]
Legal Proceedings [Line Items]
Loss contingency, damages sought, value	$ 139.9
U.S. Patent No. 8,404,215 [Member]
Legal Proceedings [Line Items]
Expiry of patent		2032-03
U.S. Patent No. 8,642,012 [Member]
Legal Proceedings [Line Items]
Expiry of patent		2030-09
U.S. Patent No. 5,968,979 [Member]
Legal Proceedings [Line Items]
Expired date of patent		Feb. 7, 2015
Extended Expiry date of patent		Feb. 7, 2016
Final extension term granted by USPTO		1267 days
PENNSAID 2% [Member]
Legal Proceedings [Line Items]
Prevention period from approving the ANDA		30 months
Actavis Settlement Agreement [Member]
Legal Proceedings [Line Items]
Settlement and license agreement date		Oct. 1, 2015
Non-exclusive license agreement term		180 days
License agreement generic entry date		Dec. 23, 2022
Perrigo Settlement Agreement [Member]
Legal Proceedings [Line Items]
Settlement and license agreement date		May 6, 2015
Effective date of settlement and license agreement		Jan. 10, 2029
Taro Settlement Agreement [Member]
Legal Proceedings [Line Items]
Settlement and license agreement date		Sep. 9, 2015
Effective date of settlement and license agreement		Jan. 10, 2029
Amneal settlement agreement [Member]
Legal Proceedings [Line Items]
Settlement and license agreement date		Apr. 18, 2016
Effective date of settlement and license agreement		Jan. 10, 2029

Debt Agreements - Outstanding D

Debt Agreements - Outstanding Debt Balances (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
2023 Senior Notes	$ 475,000	$ 475,000
Exchangeable Senior Notes due 2022	400,000	400,000
Total face value	1,272,000	1,273,000
Debt discount	(123,885)	(127,885)
Deferred financing fees	(7,935)	(8,359)
Total long-term debt	1,140,180	1,136,756
Less: current maturities	4,000	4,000
Long-term debt, net of current maturities	1,136,180	1,132,756
2015 Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt Facility	$ 397,000	$ 398,000

Debt Agreements - Outstanding71

Debt Agreements - Outstanding Debt Balances (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2016
2023 Senior Notes [Member]
Debt Instrument [Line Items]
Maturity year of debt instrument	2,023
Exchangeable Senior Notes due 2022 [Member]
Debt Instrument [Line Items]
Maturity year of debt instrument	2,022

Debt Agreements - Additional In

Debt Agreements - Additional Information (Detail)	May. 07, 2015USD ($)	Apr. 29, 2015USD ($)	Jun. 17, 2014USD ($)	Nov. 22, 2013USD ($)	Mar. 31, 2016USD ($)d$ / shares	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)shares	Mar. 13, 2015USD ($)	Sep. 19, 2014USD ($)
Debt Instrument [Line Items]
Exchangeable Senior Notes due 2022					$ 400,000,000		$ 400,000,000
Initial debt discount					123,885,000		127,885,000
Convertible Senior Notes				$ 150,000,000			61,000,000
Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate				5.00%
Non-cash charge related to extinguishment of debt							$ 10,100,000
Net proceeds received				$ 143,600,000
Notes fees				$ 6,400,000
Initial conversion, number of shares | shares							11,368,921
Cash payment to holders							$ 10,000,000
Accrued and unpaid interest							900,000
Aggregate principal amount outstanding							$ 0
35% of 6.625% Senior Notes due 2023 [Member] | Prior to May 1, 2018 [Member]
Debt Instrument [Line Items]
Convertible senior notes sold, percentage		106.625%
Exchangeable Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, fair value					$ 340,800,000
Interest rate					2.50%
Maturity year of debt instrument					2,022
Maturity date of debt instrument					Mar. 15, 2022
Convertible senior notes sold, percentage					100.00%
Debt Instrument, Convertible, Conversion Ratio (in shares per $1,000 principal amount)					34.8979
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 28.66
Debt instrument convertible minimum percentage					130.00%
Debt instrument number of trading days | d					20
Debt instrument consecutive trading days					30 days
Carrying amount of liability component					$ 268,900,000
Carrying amount of equity component					119,100,000
Initial proceeds from convertible debt instrument					387,200,000	$ 388,000,000
Initial debt discount					$ 131,100,000
Exchangeable Senior Notes [Member] | Conversion Condition One [Member]
Debt Instrument [Line Items]
Debt instrument convertible minimum percentage					130.00%
Debt instrument number of trading days | d					20
Debt instrument consecutive trading days					30 days
Exchangeable Senior Notes [Member] | Conversion Condition Two [Member]
Debt Instrument [Line Items]
Debt instrument number of trading days | d					5
Debt instrument consecutive trading days					10 days
Convertible senior notes, principal payment					$ 1,000,000
Debt instrument convertible maximum percentage					98.00%
Exchangeable Senior Notes [Member] | Horizon Investment [Member]
Debt Instrument [Line Items]
Exchangeable Senior Notes due 2022								$ 400,000,000
Interest rate					2.50%
Maturity year of debt instrument					2,022
Net proceeds from senior notes					$ 387,200,000
2023 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, fair value					$ 415,600,000
Interest rate		6.625%
Maturity year of debt instrument					2,023
2023 Senior Notes [Member] | Prior to May 1, 2018 [Member]
Debt Instrument [Line Items]
Convertible senior notes sold, percentage		100.00%
Debt instrument redemption description					The 2023 Senior Notes may be redeemed at any time at specified redemption prices, plus accrued and unpaid interest to the redemption date. At any time prior to May?1, 2018, some or all of the 2023 Senior Notes may be redeemed at a price equal to 100% of the aggregate principal amount thereof, plus a make-whole premium and accrued and unpaid interest to the redemption date. Also prior to May?1, 2018, up to 35% of the aggregate principal amount of the 2023 Senior Notes may be redeemed at a redemption price of 106.625% of the aggregate principal amount thereof, plus accrued and unpaid interest, with the net proceeds of certain equity offerings. In addition, the 2023 Senior Notes may be redeemed in whole but not in part at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest and additional amounts, if any, to, but excluding, the redemption date, if on the next date on which any amount would be payable in respect of the 2023 Senior Notes, HPI or any guarantor is or would be required to pay additional amounts as a result of certain tax related events.
2023 Senior Notes [Member] | Maximum [Member] | Prior to May 1, 2018 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt redeemed, percentage		35.00%
Hyperion Therapeutics, Inc. [Member] | 2023 Senior Notes [Member]
Debt Instrument [Line Items]
Exchangeable Senior Notes due 2022		$ 475,000,000
Maturity year of debt instrument					2,023
Maturity date of debt instrument					May 1, 2023
Debt instrument redemption description					If the Company undergoes a change of control, HPI will be required to make an offer to purchase all of the 2023 Senior Notes at a price in cash equal to 101% of the aggregate principal amount thereof plus accrued and unpaid interest to, but not including, the repurchase date. If the Company or certain of its subsidiaries engages in certain asset sales, HPI will be required under certain circumstances to make an offer to purchase the 2023 Senior Notes at 100% of the principal amount thereof, plus accrued and unpaid interest to the repurchase date.
Redemption price percentage of principal amount of debt instrument on change of control		101.00%
2015 Term Loan Facility [Member]
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity	$ 400,000,000
LIBOR floor rate	1.00%
Interest rate description					Loans under the 2015 Term Loan Facility bear interest, at each borrower’s option, at a rate equal to either the London Inter-Bank Offer Rate (“LIBOR”), plus an applicable margin of 3.5% per year (subject to a 1.0% LIBOR floor), or the adjusted base rate plus 2.5%. The adjusted base rate is defined as the greater of (a) LIBOR (using one-month interest period) plus 1%, (b) prime rate, (c) fed funds plus ½ of 1%, and (d) 2%.
Cut off percentage for defining limited liability subsidiaries, portion of capital stock held maximum	65.00%
Proceeds from debt issuances, percentage on excess cash flow	50.00%
Proceeds from debt issuances, reduction percentage on excess cash flow	25.00%
Proceeds from debt issuances, percentage on first lien leverage ratio	0.00%
First lien leverage ratio, maximum	225.00%
First lien leverage ratio, minimum	175.00%
Principal amount of loan, amortization percentage	1.00%
Credit agreement, description					HPI is required to make mandatory prepayments of loans under the 2015 Term Loan Facility (without payment of a premium) with (a) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (b) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions), (c) net cash proceeds from issuances of debt (other than certain permitted debt), and (d) beginning with the fiscal year ending December 31, 2016, 50% of the Company’s excess cash flow (subject to decrease to 25% or 0% if the Company’s first lien leverage ratio is less than 2.25:1 and 1.75:1, respectively). The loans under the 2015 Term Loan Facility will amortize in equal quarterly installments in an aggregate annual amount equal to 1% of the original principal amount thereof, with any remaining balance payable on the final maturity date of the loans under the 2015 Term Loan Facility.
2015 Term Loan Facility [Member] | Hyperion Therapeutics, Inc. [Member] | 2015 Offering [Member]
Debt Instrument [Line Items]
Debt instrument, fair value					$ 379,100,000
2015 Term Loan Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt instrument variable rate	3.50%
Line of credit facility borrowing capacity	$ 400,000,000
2015 Term Loan Facility [Member] | Adjusted Base Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate	2.50%
2014 Term Loan Facility [Member]
Debt Instrument [Line Items]
LIBOR floor rate			1.00%
Interest rate description					Term Loan Facility”) bore interest, at each borrower’s option, at a rate equal to either the LIBOR, plus an applicable margin of 8.0% per year (subject to a 1.0% LIBOR floor), or the prime lending rate, plus an applicable margin equal to 7.0% per year.
Proceeds from credit facility			$ 300,000,000
Credit facility maturity term			5 years
Repayment of debt outstanding amount	$ 300,000,000
Non-cash charge related to extinguishment of debt	$ 56,800,000
2014 Term Loan Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt instrument variable rate			8.00%
Line of credit facility borrowing capacity									$ 300,000,000
2014 Term Loan Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate			7.00%

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Subsidiary, Sale of Stock [Line Items]
Shares issued in connection with the exercise of stock options	123,924
Proceeds from exercise of stock options	$ 919	$ 1,789
Ordinary shares issued	160,634,955		160,069,067
Restricted Stock Units [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary shares issued	469,725
Performance Stock Units [Member]
Subsidiary, Sale of Stock [Line Items]
Ordinary shares issued	13,584

Share-Based Incentive Plans - A

Share-Based Incentive Plans - Additional Information (Detail) - USD ($)	Feb. 25, 2016	Mar. 23, 2015	Jul. 28, 2011	Jan. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Nov. 05, 2014	May. 17, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Granted					1,471,620
Stock options contractual term					10 years
Share-based compensation expense					$ 27,612,000	$ 6,674,000
Expected volatility assumption based on historical volatility, in percentage					74.00%	77.40%
Tax benefit recognized from stock-based compensation expense					$ 0
Tax benefits realized from stock options exercised					0
Pre-tax unrecognized compensation expense for all unvested share-based awards					$ 276,900,000
Cash Long-Term Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Trading days					20 days
Implied 20-day VWAP					$ 18.37
Bonus payable under cash bonus program									$ 16,500,000
Cash Bonus Program, description					Participants in the Cash Bonus Program will be eligible for a specified cash bonus. The Cash Bonus Program pool funding of approximately $16.5 million was determined based on the Company’s actual TSR over the period from November 5, 2014 to May 6, 2015, and the bonus will be earned and payable only if the TSR for the period from November 5, 2014 to November 4, 2017 is greater than 15%. The portion of the total bonus pool payable to individual participants is based on allocations established by the Company’s compensation committee. Participants must remain employed by the Company through November 4, 2017 unless a participant’s earlier departure from employment is due to death, disability, termination without cause or a change in control transaction. Bonus payments under the Cash Bonus Program, if any, will be made after November 4, 2017.
Estimated fair value of award					$ 4,700,000		$ 6,000,000
Decrease in valuation of cash bonus program					$ 100,000
Valuation date stock price					$ 16.57
Expected volatility assumption based on historical volatility, in percentage					72.32%
Expected volatility assumption based on historical volatility, in Years					1 year 7 months 6 days
Risk free rate					0.67%
Risk free rate remaining term					1 year 7 months 6 days
Performance Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Granted				260,000	260,000
Options outstanding expected to vest								25,000
Trading days		20 days
Implied 20-day VWAP		$ 21.50
Share-based compensation expense					$ 12,700,000
Valuation date stock price						$ 22.77
Expected volatility assumption based on historical volatility, in percentage						67.30%
Risk free rate						1.00%
Performance Stock Units [Member] | Members of Executive Committee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
One year mandatory post vest holding period percentage					50.00%
Two year mandatory post vest holding period percentage					50.00%
Performance Stock Units [Member] | Nonmembers of Executive Committee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
One year mandatory post vest holding period percentage					50.00%
Maximum [Member] | TSR [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of PSU award vesting amount range					100.00%
Maximum [Member] | Performance Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Valuation date stock price					$ 21.07
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash bonus payment date					Nov. 4, 2017
Minimum [Member] | Cash Long-Term Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash Bonus Program, percentage					15.00%
Minimum [Member] | TSR [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of PSU award vesting amount range					25.00%
Minimum [Member] | Performance Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Valuation date stock price					$ 17.72
2014 ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized					9,338,059
Common stock shares reserved for future issuance					9,338,059
Reduction in number of shares authorized for issuance	5,000,000
2005 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Granted			0
2014 EIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized					956,119					15,500,000
Common stock shares reserved for future issuance					956,119
Common stock shares, number of additional shares authorized	6,000,000	14,000,000
2014 EIP [Member] | Performance Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Granted					12,565,000
2014 EIP [Member] | Performance Stock Units [Member] | Members of Executive Committee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Granted					9,173,000
2014 EIP [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized										22,052,130
2011 EIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized										10,000,000
2014 Non-Employee Equity Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized					2,251,207					2,500,000
Common stock shares reserved for future issuance					2,251,207
Reduction in number of shares authorized for issuance	1,000,000

Share-Based Incentive Plans - S

Share-Based Incentive Plans - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options, Outstanding Beginning Balance | shares	13,385,791
Options, Granted | shares	1,471,620
Options, Exercised | shares	(123,924)
Options, Forfeited | shares	(536,920)
Options, Expired | shares	(773)
Options, Outstanding Ending Balance | shares	14,195,794
Options, Exercisable as of March 31, 2016 | shares	4,931,406
Weighted Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 17.73
Weighted Average Exercise Price, Granted | $ / shares	18.55
Weighted Average Exercise Price, Exercised | $ / shares	7.86
Weighted Average Exercise Price, Forfeited | $ / shares	19.28
Weighted Average Exercise Price, Expired | $ / shares	12.68
Weighted Average Exercise Price, Outstanding Ending Balance | $ / shares	17.84
Weighted Average Exercise Price, Exercisable as of March 31,2016 | $ / shares	$ 12.16
Weighted Average Contractual Term Remaining, Outstanding as of March 31, 2016	8 years 3 months 4 days
Weighted Average Contractual Term Remaining, Exercisable as of March 31, 2016	6 years 10 months 10 days
Aggregate Intrinsic Value, Outstanding as of December 31, 2015 | $	$ 42,454
Aggregate Intrinsic Value, Exercisable as of March 31, 2016 | $	$ 30,270

Share-Based Incentive Plans - W

Share-Based Incentive Plans - Weighted Average Fair Value per Share of Stock Option Awards Granted and Assumptions Used to Value Stock Options (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate, minimum	1.30%	1.30%
Risk-free interest rate, maximum	1.80%	1.70%
Weighted average volatility	74.00%	77.40%
Expected life (in years)	6 years 1 month 6 days	6 years
Weighted average grant date fair value per share of options granted	$ 12.12	$ 14.32

Share-Based Incentive Plans -77

Share-Based Incentive Plans - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Outstanding Beginning Balance | shares	3,361,746
Number of Units, Granted | shares	336,372
Number of Units, Vested | shares	(697,500)
Number of Units, Forfeited | shares	(207,390)
Number of Units, Outstanding Ending Balance | shares	2,793,228
Weighted Average Grant-Date Fair Value Per Units, Outstanding Beginning Balance | $ / shares	$ 18.71
Weighted Average Grant-Date Fair Value Per Units, Granted | $ / shares	17.75
Weighted Average Grant-Date Fair Value Per Units, Vested | $ / shares	15.85
Weighted Average Grant-Date Fair Value Per Units, Forfeited | $ / shares	19.57
Weighted Average Grant-Date Fair Value Per Units, Outstanding Ending Balance | $ / shares	$ 19.24

Share-Based Incentive Plans -78

Share-Based Incentive Plans - Summary of Performance Stock Unit Awards (PSUs) Activity (Detail) - Performance Stock Units [Member] - $ / shares	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Outstanding Beginning Balance	13,049,000	13,049,000
Number of Units, Granted	260,000	260,000
Number of Units, Vested		(20,000)
Number of Units, Forfeited		(699,000)
Number of Units, Outstanding Ending Balance		12,590,000
Weighted Average Grant-Date Fair Value Per Units, Granted		$ 7.99
Weighted Average Grant-Date Fair Value Per Units, Vested		18.97
Weighted Average Grant-Date Fair Value Per Units, Forfeited		$ 14.39
Average Illiquidity discount, Granted		8.20%
Average Illiquidity discount, Vested		0.00%
Average Illiquidity discount, Forfeited		17.10%
Recorded Weighted Average Fair Value Per Unit, Granted		$ 7.34
Recorded Weighted Average Fair Value Per Unit, Vested		18.97
Recorded Weighted Average Fair Value Per Unit, Forfeited		$ 11.93

Share-Based Incentive Plans -79

Share-Based Incentive Plans - Summary of Vesting Tranches (Detail)	3 Months Ended
	Mar. 31, 2016
Performance Stock Units [Member] | Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percent of Total PSU Award	33.30%
Beginning of Performance Measurement Period	Mar. 23, 2015
End of Performance Measurement Period	Dec. 22, 2017
Performance Stock Units [Member] | Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percent of Total PSU Award	33.30%
Beginning of Performance Measurement Period	Mar. 23, 2015
End of Performance Measurement Period	Mar. 22, 2018
Performance Stock Units [Member] | Tranche Three [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percent of Total PSU Award	33.30%
Beginning of Performance Measurement Period	Mar. 23, 2015
End of Performance Measurement Period	Jun. 22, 2018
Performance Stock Units [Member] | Vesting Amount 25% [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percent of Total PSU Award	25.00%
TSR Achieved Percentage	15.00%
Performance Stock Units [Member] | Vesting Amount 50% [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percent of Total PSU Award	50.00%
TSR Achieved Percentage	30.00%
Performance Stock Units [Member] | Vesting Amount 75% [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percent of Total PSU Award	75.00%
TSR Achieved Percentage	45.00%
Performance Stock Units [Member] | Vesting Amount 100% [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percent of Total PSU Award	100.00%
TSR Achieved Percentage	60.00%
Initial Performance Stock Units [Member] | Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Length of Performance Measurement Period (Years)	2 years 9 months
Initial Performance Stock Units [Member] | Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Length of Performance Measurement Period (Years)	3 years
Initial Performance Stock Units [Member] | Tranche Three [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Length of Performance Measurement Period (Years)	3 years 3 months

Share-Based Incentive Plans -80

Share-Based Incentive Plans - Summary of Significant Valuation Assumption (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average volatility	74.00%	77.40%
Risk free rate, minimum	1.30%	1.30%
Risk free rate, maximum	1.80%	1.70%
Performance Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Valuation date stock price		$ 22.77
Weighted average volatility		67.30%
Expected volatility, minimum	76.80%
Expected volatility, maximum	77.60%
Risk free rate		1.00%
Risk free rate, minimum	1.00%
Risk free rate, maximum	1.20%
Performance Stock Units [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Valuation date stock price	$ 17.72
Performance Stock Units [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Valuation date stock price	$ 21.07

Share-Based Incentive Plans -81

Share-Based Incentive Plans - Summary of Average Estimated Fair Value of PSU after Applicable Discount of Illiquidity (Detail) - Performance Stock Units [Member] - $ / shares	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Granted	260,000	260,000
Weighted Average Fair Value Per Unit		$ 7.99
Average Illiquidity Discount		8.20%
Recorded Weighted Average Fair Value Per Unit		$ 7.34
2014 EIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Granted		12,565,000
Weighted Average Fair Value Per Unit		$ 14.75
Average Illiquidity Discount		15.60%
Recorded Weighted Average Fair Value Per Unit		$ 12.46
Members of Executive Committee [Member] | 2014 EIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Granted		9,173,000
Weighted Average Fair Value Per Unit		$ 15.18
Average Illiquidity Discount		18.30%
Recorded Weighted Average Fair Value Per Unit		$ 12.40
Members of Non-Executive Committee [Member] | 2014 EIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Granted		3,392,000
Weighted Average Fair Value Per Unit		$ 13.60
Average Illiquidity Discount		7.30%
Recorded Weighted Average Fair Value Per Unit		$ 12.60

Share-Based Incentive Plans -82

Share-Based Incentive Plans - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 27,612	$ 6,674
Research and Development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	2,125	458
Sales and Marketing [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	5,678	2,801
General and Administrative [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 19,809	$ 3,415

Income Taxes - (Benefit) Expens

Income Taxes - (Benefit) Expense for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Loss before (benefit) expense for income taxes	$ (46,849)	$ (17,640)
(Benefit) expense for income taxes	(1,443)	1,913
NET LOSS	$ (45,406)	$ (19,553)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Taxes [Line Items]
(Benefit) expense for income taxes	$ (1,443)	$ 1,913
Crealta Holdings LLC [Member]
Income Taxes [Line Items]
Increase to net deferred tax liability	$ 20,800